CUMULATIVE
SUPPLEMENT 5
JAN'97-MAY'97



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF MANAGEMENT
DIVISION OF DATABASE MANAGEMENT

Prepared By
Division of Database Management
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Cumulative Supplement 5

MAY 1997

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

CUMULATIVE SUPPLEMENT 5
MAY 1997

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 17th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

New additions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The shaded print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements (hard copy only) for this edition. However, the overstruck data in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements (hard copy).

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 16th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 17th Edition.

1.2 COURT ORDER AFFECTING URUGUAY ROUND AGREEMENTS ACT-EXTENDED PATENTS

As a result of the April 4, 1996, decision of the United States Court of Appeals for the Federal Circuit in Merck, et al. v. Kessler, patent expiration dates for certain patents subject to patent term extensions under the Uruguay Round Agreements Act and to the patent term extension provisions at 35 U.S.C. § 156 may be changed. FDA has published a notice in the March 14, 1997, *Federal Register* advising NDA and NADA

applicants that patent expiration dates changed by the Merck decision must be submitted within 60 days. Because there may be changes in listed patents as a result of the Merck decision, users of this publication should consult the most recent supplement, and are encouraged to confirm that patent information upon which they intend to rely is current. (See the *Patent and Exclusivity Addendum* to the *Approved Drug Products with Therapeutic Equivalence Evaluations*, 16th Edition that explains the background information on this court decision).

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will automatically reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. However, when the applicant name change is one which may not be easily recognized or located in the listing (e.g., White Towne Paulsen [Former Abbreviated Name] is changed to Whiteworth Towne [New Abbreviated Name], the name change will appear in this section and will be identified with an asterisk.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP (CIBA GEIGY)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CIBA GEIGY CORP PHARMACEUTICALS DIV (CIBA GEIGY)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)
CIBA PHARMACEUTICAL CO DIV CIBA GEIGY CORP (CIBA)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)
CIBA SELF MEDICATION INC DIV CIBA GEIGY CORP (CIBA)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
CIBA VISION OPHTHALMICS DIV CIBA VISION CORP (CIBA)	CIBA VISION CORPORATION A NOVARTIS COMPANY (CIBA)
FERRING LABORATORIES INC (FERRING)	FERRING PHARMACEUTICALS INC (FERRING)
GEIGY PHARMACEUTICALS DIV CIBA GEIGY CORP (GEIGY)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)
LEMMON CO SUB TAG PHARMACEUTICAL INC (LEMMON)	BIOCRAFT LABORATORIES INC (BIOCRAFT) **THEN CHANGED TO** TEVA PHARMACEUTICALS USA (TEVA)
SANDOZ CONSUMER HEALTH CARE GROUP DIV SANDOZ PHARMACEUTICALS (SANDOZ)	NOVARTIS CONSUMER HEALTH INC (NOVARTIS)
SANDOZ PHARMACEUTICALS CORP DIV SANDOZ INC (SANDOZ)	NOVARTIS PHARMACEUTICAL CORP (NOVARTIS)
SANDOZ RESEARCH INSTITUTE INC (SANDOZ)	NOVARTIS PHARMACEUTCAL CORP (NOVARTIS)
SANOFI WINTHROP INC (SANOFI WINTHROP)	SANOFI PHARMACEUTICAL INC (SANOFI)
SURVIVAL TECHNOLOGY INC (SURVIVAL TECH)	MERIDIAN MEDICAL TECHNOLOGIES INC (MERIDIAN MEDCL TECHN)

1.4 ACYCLOVIR 200MG TABLET-REFERENCE LISTED DRUG

Novapharm's single source acyclovir tablets have been declared to be a reference listed drug for the 200 mg tablet in addition to the acylcovir (Zovirax) 800 mg tablet of the innovator. A generic firm wishing to submit an ANDA for a duplicate of the 200 mg acyclovir tablet will be eligible for a waiver of the *in vivo* determination of bioequivalence (1) if their product is proportionally similar in its active and inactive ingredients to their own 800 mg acyclovir tablet and (2) by doing an acceptable comparative dissolution test (dissolution profile) against Novopharm's 200 mg acyclovir reference listed drug.

Before a waiver of the *in vivo* determination of bioequivalence can be granted for the 200 mg acyclovir tablet, the generic firm must have completed an acceptable fasting and fed study comparing their acyclovir 800 mg tablet against the Zovirax 800 mg tablet.

For further information on the study designs, you should contact the Division of Bioequivalence, Office of Generic Drugs.

1.5 AVAILABILITY OF THE PUBLICATION AND UPDATING PROCEDURES

The *Approved Drug Products with Therapeutic Equivalence Evaluations* (Prescription Drug Products, OTC Drug Products and the Discontinued Drug Product Lists) is available on diskette, on a quarterly basis, from the National Technical Information Service. The telephone number for the Subscription Department is (703) 487-6430. Written inquiries regarding this subscription may be forwarded to 5285 Port Royal Road Springfield, VA 22161.

The following *Approved Drug Products with Therapeutic Equivalence Evaluations* files are now available on Internet and are updated each October and April: Prescription Drug Product List; OTC Drug Products; Discontinued Drug Products; and Appendices. The update in October will include drug products that have been approved through August and the update in April will include drug products that have been approved through December.

These files may be accessed on the Internet's World Wide Web. FDA's Internet site replaced the Agency's electronic bulletin board. To access the CDER Home Page, use this Uniform Resource Locator (URL): http://www.fda.gov/cder. You do not need an Internet connection to reach the FDA Home Page; you can use the free dial-up connection (800) 222-0185 for text based, non-graphical use only. For further assistance, please call (301) 443-4908.

The Prescription Drug Products and OTC Drug Product files will be available on a monthly basis in the near future.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1996) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1996*	MAR 1997	JUN 1997	SEP 1997
DRUG PRODUCTS LISTED	9392	9493		
SINGLE SOURCE	2383 (25.4%)	2387 (25.1%)		
MULTISOURCE	6905 (73.5%)	6991 (73.7%)		
THERAPEUTICALLY EQUIVALENT	6463 (68.8%)	6549 (69.0%)		
NOT THERAPEUTICALLY EQUIVALENT	442 (4.7%)	442 (4.7%)		
EXCEPTIONS[1]	104 (1.1%)	115 (1.2%)		
NEW MOLECULAR ENTITIES APPROVED	--	6		
NUMBER OF APPLICANTS	650	662		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

*Exceptions were originally included in the total count of the Multisource Drug Products. Beginning with December 1996, exceptions will no longer be included in the Multisource Drug Products total count, but will be included in the total count of the Drug Products Listed.

ACARBOSE

TABLET; ORAL

	PRECOSE			
> ADD >	BAYER	25MG	N20482 004	
> ADD >			MAY 29, 1997	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

	BUTALBITAL, ACETAMINOPHEN, CAFFEINE			
AB	GRAHAM DM	**325MG;50MG;40MG**	**N88743 001**	
			JUL 18, 1985	
AB		**325MG;50MG;40MG**	**N88765 001**	
			MAR 27, 1985	
AB		**325MG;50MG;40MG**	**N89067 001**	
			APR 19, 1985	
@		325MG;50MG;40MG	N88743 001	
			JUL 18, 1985	
@		325MG;50MG;40MG	N88765 001	
			MAR 27, 1985	
@		325MG;50MG;40MG	N89067 001	
			APR 19, 1985	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

	HYDROCODONE BITARTRATE AND ACETAMINOPHEN			
AA	EON	**500MG;5MG**	**N40149 001**	
			JAN 27, 1997	
AA		**750MG;7.5MG**	**N40149 002**	
			JAN 27, 1997	
AA	VINTAGE PHARMS	**500MG;2.5MG**	**N40144 002**	
			APR 25, 1997	
AA		**650MG;7.5MG**	**N40155 001**	
			APR 14, 1997	
AA	WATSON LABS	**500MG;10MG**	**N40148 002**	
			FEB 14, 1997	
	LORTAB			
> DLT > **AA**	+ GRAHAM DM	**500MG;10MG**	**N40100 001**	
> DLT >			JAN 26, 1996	
> ADD > **AA**	+ UCB	**500MG;10MG**	**N40100 001**	
> ADD >			JAN 26, 1996	
	NORCO			
	+ WATSON LABS	325MG;10MG	N40148 001	
			FEB 14, 1997	

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN			
AB	VINTAGE PHARMS	**650MG;100MG**	**N74843 001**	
			FEB 12, 1997	

ACETAZOLAMIDE

TABLET; ORAL

	ACETAZOLAMIDE			
> ADD > **AB**	TARO	**125MG**	**N40195 001**	
> ADD >			MAY 28, 1997	
> ADD > **AB**		**250MG**	**N40195 002**	
> ADD >			MAY 28, 1997	

ACETIC ACID, GLACIAL; DESONIDE

SOLUTION/DROPS; OTIC

TRIDESILON			
BAYER	2%;0.05%	N17914 001	
@	2%;0.05%	N17914 001	

ACYCLOVIR

CAPSULE; ORAL

	ACYCLOVIR			
AB	AESGEN	**200MG**	**N74833 001**	
			APR 22, 1997	
AB	ESI LEDERLE	**200MG**	**N74872 001**	
			APR 22, 1997	
AB	LEK PHARM	**200MG**	**N74750 001**	
			APR 22, 1997	
AB	LEMMON	**200MG**	**N74828 001**	
			APR 22, 1997	
AB	MYLAN	**200MG**	**N74727 001**	
			APR 22, 1997	
AB	NOVOPHARM	**200MG**	**N74578 001**	
			APR 22, 1997	
AB	ROXANE	**200MG**	**N74570 002**	
			APR 22, 1997	
AB	ZENITH GOLDLINE	**200MG**	**N74674 001**	
			APR 22, 1997	
	ZOVIRAX			
AB +	GLAXO WELLCOME	**200MG**	**N18828 001**	
			JAN 25, 1985	

ACYCLOVIR

SUSPENSION; ORAL

	ACYCLOVIR			
AB	ALPHARMA	**200MG/5ML**	**N74738 001**	APR 28, 1997
	ZOVIRAX			
AB	+ GLAXO WELLCOME	**200MG/5ML**	**N19909 001**	DEC 22, 1989

TABLET; ORAL

	ACYCLOVIR			
AB	ESI LEDERLE	**400MG**	**N74834 001**	APR 24, 1997
AB		**800MG**	**N74834 002**	APR 24, 1997
AB	LEK PHARM	**400MG**	**N74658 001**	APR 22, 1997
AB		**800MG**	**N74658 002**	APR 22, 1997
AB	NOVOPHARM	**400MG**	**N74556 002**	APR 22, 1997
AB		**800MG**	**N74556 003**	APR 22, 1997
	+	200MG	N74556 001	APR 22, 1997
AB	ZENITH GOLDLINE	**400MG**	**N74836 001**	APR 22, 1997
AB		**800MG**	**N74836 002**	APR 22, 1997
	ZOVIRAX			
AB	GLAXO WELLCOME	**400MG**	**N20089 001**	APR 30, 1991
AB	+	**800MG**	**N20089 002**	APR 30, 1991

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR SODIUM			
AP	ABBOTT	**EQ 500MG BASE/VIAL**	**N74758 001**	APR 22, 1997
AP		**EQ 1GM BASE/VIAL**	**N74758 002**	APR 22, 1997
AP	BEDFORD	**EQ 500MG BASE/VIAL**	**N74596 002**	APR 22, 1997
AP		**EQ 1GM BASE/VIAL**	**N74596 001**	APR 22, 1997

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

	ACYCLOVIR SODIUM			
	+ FAULDING	EQ 25MG BASE/ML	N74720 001	APR 22, 1997
AP	SANOFI WINTHROP	**EQ 500MG BASE/VIAL**	**N74663 001**	APR 22, 1997
AP		**EQ 1GM BASE/VIAL**	**N74663 002**	APR 22, 1997
	ZOVIRAX			
AP	+ GLAXO WELLCOME	**EQ 500MG BASE/VIAL**	**N18603 001**	OCT 22, 1982
AP	+	**EQ 1GM BASE/VIAL**	**N18603 002**	JUN 29, 1989

ALENDRONATE SODIUM

TABLET; ORAL

	FOSAMAX		
	MERCK	EQ 5MG BASE	N20560 003 APR 25, 1997

ALPRAZOLAM

TABLET; ORAL

	ALPRAZOLAM			
AB	ROYCE LABS	**0.25MG**	**N74479 001**	JAN 21, 1997
AB		**0.5MG**	**N74479 002**	JAN 21, 1997
AB		**1MG**	**N74479 003**	JAN 21, 1997

AMIKACIN SULFATE

INJECTABLE; INJECTION

	AMIKACIN SULFATE			
AP	ELKINS SINN	**EQ 50MG BASE/ML**	**N63274 001**	MAY 18, 1992
	@	EQ 50MG BASE/ML	N63274 001	MAY 18, 1992

AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

ABBOTT	EQ 500MG BASE/100ML	N64146 001	APR 02, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
ABBOTT 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 004 NOV 07, 1988

@ 5%;36.8MG/100ML;25GM/100ML; 51MG/100ML;22.4MG/100ML;261MG/100ML; 205MG/100ML N19683 004 NOV 07, 1988

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
CLINIMIX E 2.75/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 002 MAR 26, 1997

CLINIMIX E 2.75/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 005 MAR 26, 1997

CLINIMIX E 2.75/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 2.75%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;217MG/100ML; 112MG/100ML N20678 001 MAR 26, 1997

CLINIMIX E 4.25/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;10GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 009 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
CLINIMIX E 4.25/20 SULFITE-FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;20GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 011 MAR 26, 1997

CLINIMIX E 4.25/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;25GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 012 MAR 26, 1997

CLINIMIX E 4.25/5 SULFITE-FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 4.25%;33MG/100ML;5GM/100ML; 51MG/100ML;261MG/100ML;297MG/100ML; 77MG/100ML N20678 008 MAR 26, 1997

CLINIMIX E 5/10 SULFITE-FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;10GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 016 MAR 26, 1997

CLINIMIX E 5/15 SULFITE-FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;15GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 017 MAR 26, 1997

CLINIMIX E 5/20 SULFITE-FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;20GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 018 MAR 26, 1997

CLINIMIX E 5/25 SULFITE-FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
+ BAXTER HLTHCARE 5%;33MG/100ML;25GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML N20678 019 MAR 26, 1997

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

> ADD >		CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER			
> ADD >	+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML; 261MG/100ML;340MG/100ML; 59MG/100ML	N20678 021 MAR 26, 1997	

AMINOPHYLLINE

INJECTABLE; INJECTION

		AMINOPHYLLIN			
AP	+	**SEARLE**	**25MG/ML**	**N87243 001 MAY 24, 1982**	
	@		25MG/ML	N87243 001 MAY 24, 1982	
		AMINOPHYLLINE			
AP		**ELKINS SINN**	**25MG/ML**	**N87239 001**	
AP	+		**25MG/ML**	**N87239 001**	

TABLET; ORAL

		AMINOPHYLLINE			
> DLT >	BD	HALSEY	100MG	N84674 001	
> ADD >	@		100MG	N84674 001	

TABLET, EXTENDED RELEASE; ORAL

		PHYLLOCONTIN			
	+	PURDUE FREDERICK	225MG	N86760 001	
	@		225MG	N86760 001	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

		AMITRIPTYLINE HCL			
> DLT >	BP	HALSEY	10MG	N85923 001	
> DLT >	BP		50MG	N85925 001	
> DLT >	BP		75MG	N85926 001	
> DLT >				MAY 20, 1983	
> DLT >	BP		100MG	N85927 001	
> DLT >				MAY 20, 1983	
> ADD >	@		10MG	N85923 001	
> ADD >	@		50MG	N85925 001	
> ADD >	@		75MG	N85926 001	
> ADD >				MAY 20, 1983	

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

		AMITRIPTYLINE HCL			
> ADD >	@	HALSEY	100MG	N85927 001	
> ADD >				MAY 20, 1983	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

		LIMBITROL			
AB	+	**ROCHE**	**EQ 25MG BASE;10MG**	**N16949 002**	
		LIMBITROL DS			
AB	+	ROCHE	**EQ 25MG BASE;10MG**	**N16949 002**	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

		ETRAPON-A			
> DLT >	BP	SCHERING	10MG;4MG	N14713 002	
> DLT >	@		10MG;4MG	N14713 002	

AMOXICILLIN

CAPSULE; ORAL

		AMOXIL			
AB	+	**SMITHKLINE BEECHAM**	**250MG**	**N50459 001**	
AB			**250MG**	**N62216 001**	
AB	+		**250MG**	**N62216 001**	
AB	+		**500MG**	**N50459 002**	
AB			**500MG**	**N62216 004**	
AB	+		**500MG**	**N62216 004**	
	@		250MG	N50459 001	
	@		500MG	N50459 002	

POWDER FOR RECONSTITUTION; ORAL

		AMOXIL			
AB	+	**SMITHKLINE BEECHAM**	**125MG/5ML**	**N50460 001**	
AB			**125MG/5ML**	**N62226 001**	
AB	+		**125MG/5ML**	**N62226 001**	
AB	+		**250MG/5ML**	**N50460 002**	
AB	+		**50MG/ML**	**N50460 005**	
AB			**250MG/5ML**	**N62226 002**	
AB	+		**250MG/5ML**	**N62226 002**	
AB			**50MG/ML**	**N62226 005**	
AB	+		**50MG/ML**	**N62226 005**	

AMOXICILLIN

POWDER FOR RECONSTITUTION; ORAL

	AMOXIL				
	@ SMITHKLINE BEECHAM	125MG/5ML	N50460 001	> DLT >	
	@	250MG/5ML	N50460 002	> DLT >	
	@	50MG/ML	N50460 005	> DLT >	
	LAROTID			> ADD >	
AB	SMITHKLINE BEECHAM	50MG/ML	N50460 006	> ADD >	
	@	50MG/ML	N50460 006		

AMPHOTERICIN B

OINTMENT; TOPICAL

	FUNGIZONE			
	+ APOTHECON	3%	N50313 001	
	@	3%	N50313 001	

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

	AGRYLIN			
	ROBERTS LABS	EQ 0.5MG BASE	N20333 001	
			MAR 14, 1997	
	+	EQ 1MG BASE	N20333 002	
			MAR 14, 1997	

> ADD > ARDEPARIN SODIUM

> ADD > INJECTABLE; INJECTION

> ADD >	NORMIFLO			
> ADD >	+ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	
> ADD >			MAY 23, 1997	
> ADD >	+	10,000 UNITS/0.5ML	N20227 001	
> ADD >			MAY 23, 1997	

ASPIRIN; BUTALBITAL

> DLT > TABLET; ORAL

> DLT >	AXOTAL			
> DLT >	+ SAVAGE LABS	650MG;50MG	N88305 001	
> DLT >			OCT 13, 1983	
> ADD >	@	650MG;50MG	N88305 001	
> ADD >			OCT 13, 1983	

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

	CODOXY			
AA	HALSEY	325MG;4.5MG;0.38MG	N87464 001	
			JUL 01, 1982	
	@	325MG;4.5MG;0.38MG	N87464 001	
			JUL 01, 1982	

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

	ATRACURIUM BESYLATE			
AP	ABBOTT	10MG/ML	N74633 001	
			DEC 23, 1996	
AP	FAULDING	10MG/ML	N74740 001	
			MAR 28, 1997	
AP	OHMEDA	10MG/ML	N74753 001	
			JAN 23, 1997	
	ATRACURIUM BESYLATE PRESERVATIVE FREE			
AP	ABBOTT	10MG/ML	N74633 001	
			DEC 23, 1996	
AP		10MG/ML	N74639 001	
			MAR 25, 1997	
AP	FAULDING	10MG/ML	N74741 001	
			MAR 28, 1997	
AP	OHMEDA	10MG/ML	N74768 001	
			JAN 23, 1997	
	TRACRIUM			
AP	+ GLAXO WELLCOME	10MG/ML	N18831 001	
			NOV 23, 1983	
AP	+	10MG/ML	N18831 002	
			JUN 20, 1985	
	TRACRIUM PRESERVATIVE FREE			
AP	+ GLAXO WELLCOME	10MG/ML	N18831 001	
			NOV 23, 1983	

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

	DIPHENOXYLATE HCL AND ATROPINE SULFATE			
AA	ROXANE	0.025MG;2.5MG	N86057 001	
	@	0.025MG;2.5MG	N86057 001	
	DIPHENOXYLATE HCL W/ ATROPINE SULFATE			
AA	KV PHARM	0.025MG;2.5MG	N85659 001	
	@	0.025MG;2.5MG	N85659 001	

AZITHROMYCIN DIHYDRATE

INJECTABLE; INJECTION
ZITHROMAX
+ PFIZER — EQ 500MG BASE/VIAL — N50733 001 JAN 30, 1997

BACITRACIN

INJECTABLE; INJECTION
> ADD > BACIIM
> ADD > AP PHARMA TEK — 50,000 UNITS/VIAL — N64153 001 MAY 09, 1997
> ADD >
BACITRACIN
> ADD > AP + PHARMACIA AND UPJOHN — 50,000 UNITS/VIAL — N60733 002

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; TOPICAL
CORTISPORIN
* GLAXO WELLCOME — 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM — N50168 002 MAY 04, 1984
+ MONARCH PHARMS — 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 5,000 UNITS/GM — N50168 002 MAY 04, 1984

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
> DLT > AB FOUGERA — EQ 0.1% BASE — N18861 001 AUG 31, 1983
> DLT >
> ADD > AB + — EQ 0.1% BASE — N18861 001 AUG 31, 1983
> ADD >
> DLT > VALISONE
> DLT > AB * SCHERING — EQ 0.1% BASE — N16322 001
> DLT > — EQ 0.01% BASE — N16322 002
> ADD > @ — EQ 0.01% BASE — N16322 002
> ADD > @ — EQ 0.1% BASE — N16322 001

LOTION; TOPICAL
BETAMETHASONE VALERATE
> DLT > AB FOUGERA — EQ 0.1% BASE — N18866 001 AUG 31, 1983
> DLT >

BETAMETHASONE VALERATE

LOTION; TOPICAL
BETAMETHASONE VALERATE
> ADD > AB + FOUGERA — EQ 0.1% BASE — N18866 001 AUG 31, 1983
> ADD >
> DLT > VALISONE
> DLT > AB * SCHERING — EQ 0.1% BASE — N16932 001
> ADD > @ — EQ 0.1% BASE — N16932 001

OINTMENT; TOPICAL
BETAMETHASONE VALERATE
> DLT > AB FOUGERA — EQ 0.1% BASE — N18865 001 AUG 31, 1983
> DLT >
> ADD > AB + — EQ 0.1% BASE — N18865 001 AUG 31, 1983
> ADD >
> DLT > VALISONE
> DLT > AB * SCHERING — EQ 0.1% BASE — N16740 001
> ADD > @ — EQ 0.1% BASE — N16740 001

BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
BETOPTIC PILO
+ ALCON — EQ 0.25% BASE;1.75% — N20619 001 APR 17, 1997

BLEOMYCIN SULFATE

INJECTABLE; INJECTION
BLENOXANE
> ADD > AP + BRISTOL MYERS SQUIBB — EQ 30 UNITS BASE/VIAL — N50443 002 SEP 07, 1995
> ADD >
BLEOMYCIN SULFATE
> ADD > AP PHARMACIA AND UPJOHN — EQ 30 UNITS BASE/VIAL — N64084 002 JUN 01, 1996
> ADD >
> DLT > * — EQ 30 UNITS BASE/VIAL — N64084 002 JUN 01, 1996
> DLT >

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER
AP * BAXTER HLTHCARE — 200MG/100ML — N19837 002 APR 12, 1989

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+ **BAXTER HLTHCARE**	**400MG/100ML**	**N19837 001**	**APR 12, 1989**
	@	200MG/100ML	N19837 002	APR 12, 1989
	@	400MG/100ML	N19837 001	APR 12, 1989

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN

+	ALLERGAN	0.5%	N20490 001 MAR 13, 1997

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN

>ADD>	+	GLAXO WELLCOME	100MG	N20358 002 OCT 04, 1996
>ADD>	+		150MG	N20358 003 OCT 04, 1996

ZYBAN

>ADD>		GLAXO WELLCOME	100MG	N20711 002 MAY 14, 1997
>ADD>			150MG	N20711 003 MAY 14, 1997

BUTOCONAZOLE NITRATE

CREAM; VAGINAL
FEMSTAT ONE

+	SYNTEX	2%	N19881 001 FEB 07, 1997

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	ABBOTT	**1MG/ML**	**N74620 001 JAN 22, 1997**

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	ABBOTT	**1MG/ML**	**N74626 001 JAN 23, 1997**
AP		**2MG/ML**	**N74620 002 JAN 22, 1997**
AP		**2MG/ML**	**N74626 002 JAN 23, 1997**

STADOL

AP	+ APOTHECON	**2MG/ML**	**N17857 004**	

STADOL PRESERVATIVE FREE

AP	+ APOTHECON	**1MG/ML**	**N17857 001**	
AP	+	**2MG/ML**	**N17857 002**	

CALCIPOTRIENE

SOLUTION; TOPICAL
DOVONEX

+	BRISTOL MYERS SQUIBB	0.005%	N20611 001 MAR 03, 1997

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

>DLT> **AP**	**MCGAW**	**20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML**	**N17510 001**	
>DLT> >ADD> >ADD>	@	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML;310MG/100ML	N17510 001	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION
LACTATED RINGER'S IN PLASTIC CONTAINER

>DLT> **AP**	**MCGAW**	**20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML**	**N18023 001**	
>DLT> >ADD> >ADD>	@	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N18023 001	

CAPTOPRIL

TABLET; ORAL
CAPOTEN

	AB	* BRISTOL MYERS SQUIBB	25MG	N18343 002
	AB		25MG	N18343 002

CAPTOPRIL

> ADD >	AB	EGIS PHARMS	12.5MG	N74748 004 MAY 29, 1997
> ADD >	AB		25MG	N74748 002 MAY 29, 1997
> ADD >	AB		50MG	N74748 001 MAY 29, 1997
> ADD >	AB		100MG	N74748 003 MAY 29, 1997
	AB	PUREPAC PHARM	12.5MG	N74640 001 MAR 31, 1997
	AB		25MG	N74640 002 MAR 31, 1997
	AB		50MG	N74640 003 MAR 31, 1997
	AB		100MG	N74640 004 MAR 31, 1997
> ADD >	AB	STASON	12.5MG	N74677 004 MAY 30, 1997
> ADD >	AB		25MG	N74677 002 MAY 30, 1997
> ADD >	AB		50MG	N74677 001 MAY 30, 1997
> ADD >	AB		100MG	N74677 003 MAY 30, 1997
	AB	WOCKHARDT	12.5MG	N74532 001 MAR 28, 1997
	AB		25MG	N74532 002 MAR 28, 1997
	AB		50MG	N74532 003 MAR 28, 1997
	AB		100MG	N74532 004 MAR 28, 1997

CARBAMAZEPINE

TABLET; ORAL
EPITOL

	AB	LEMMON	200MG	N70541 001 SEP 17, 1986
	AB	TEVA	200MG	N70541 001 SEP 17, 1986

CARBAMAZEPINE

TABLET, CHEWABLE; ORAL
EPITOL

	AB	LEMMON	100MG	N73524 001 JUL 29, 1992
	AB	TEVA	100MG	N73524 001 JUL 29, 1992

CARBIDOPA; LEVODOPA

TABLET; ORAL
CARBIDOPA AND LEVODOPA

	AB	LEMMON	10MG;100MG	N73618 001 AUG 28, 1992
	AB		25MG;100MG	N73589 001 AUG 28, 1992
	AB		25MG;250MG	N73607 001 AUG 28, 1992
	AB	TEVA	10MG;100MG	N73618 001 AUG 28, 1992
	AB		25MG;100MG	N73589 001 AUG 28, 1992
	AB		25MG;250MG	N73607 001 AUG 28, 1992

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

	AA	AMIDE PHARM	350MG	N40188 001 MAR 07, 1997

CARVEDILOL

TABLET; ORAL
COREG

> ADD >		SMITHKLINE BEECHAM	3.125MG	N20297 004 MAY 29, 1997

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

	AP	LEMMON	EQ 250MG BASE/VIAL	N63016 001 MAR 14, 1989

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

	CEFAZOLIN SODIUM					
AP	LEMMON	**EQ 500MG BASE/VIAL**	**N63016 002**	> DLT >		
			MAR 14, 1989	> DLT >		
AP		**EQ 1GM BASE/VIAL**	**N63016 003**	> DLT >		
			MAR 14, 1989	> DLT >		
AP		**EQ 5GM BASE/VIAL**	**N63018 001**	> ADD >		
			MAR 05, 1990	> ADD >		
AP		**EQ 10GM BASE/VIAL**	**N63018 002**	> ADD >		
			MAR 05, 1990	> ADD >		
AP	TEVA	**EQ 250MG BASE/VIAL**	**N63016 001**			
			MAR 14, 1989			
AP		**EQ 500MG BASE/VIAL**	**N63016 002**			
			MAR 14, 1989			
AP		**EQ 1GM BASE/VIAL**	**N63016 003**			
			MAR 14, 1989			
AP		**EQ 5GM BASE/VIAL**	**N63018 001**	> DLT >		
			MAR 05, 1990	> DLT >		
AP		**EQ 10GM BASE/VIAL**	**N63018 002**	> DLT >		
			MAR 05, 1990	> DLT >		
				> ADD >		
				> ADD >		
				> ADD >		
				> ADD >		

CEFUROXIME SODIUM

INJECTABLE; INJECTION

	CEFUROXIME SODIUM					
> ADD > **AB**	HANFORD GC	**EQ 750MG BASE/VIAL**	**N64125 001**			
> ADD >			MAY 30, 1997			
> ADD > **AP**		**EQ 1.5GM BASE/VIAL**	**N64125 002**			
> ADD >			MAY 30, 1997			
> ADD > **AP**		**EQ 7.5GM BASE/VIAL**	**N64124 001**			
> ADD >			MAY 30, 1997			
	KEFUROX					
> ADD > **AB**	LILLY	**EQ 750MG BASE/VIAL**	**N62591 001**			
> ADD >			JAN 10, 1986			
> ADD > **AB**		**EQ 750MG BASE/VIAL**	**N62592 001**			
> ADD >			JAN 10, 1986			
> DLT > **AP**		**EQ 750MG BASE/VIAL**	**N62591 001**			
> DLT >			JAN 10, 1986			
> DLT > **AP**		**EQ 750MG BASE/VIAL**	**N62592 001**			
> DLT >			JAN 10, 1986			
	ZINACEF					
> ADD > **AB**	+ GLAXO WELLCOME	**EQ 750MG BASE/VIAL**	**N50558 002**			
> ADD >			OCT 19, 1983			
> DLT > **AP**	+	**EQ 750MG BASE/VIAL**	**N50558 002**			
> DLT >			OCT 19, 1983			

CEPHALEXIN

CAPSULE; ORAL

	CEPHALEXIN					
AB	APOTHECON	**EQ 250MG BASE**	**N62973 001**			
			NOV 08, 1988			
AB		**EQ 500MG BASE**	**N62974 001**			
			NOV 23, 1988			
@		EQ 250MG BASE	N62973 001			
			NOV 08, 1988			
@		EQ 500MG BASE	N62974 001			
			NOV 23, 1988			

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

	CEFADYL					
	APOTHECON	**EQ 1GM BASE/VIAL**	**N62724 001**			
			DEC 23, 1986			
		EQ 2GM BASE/VIAL	**N62724 002**			
			DEC 23, 1986			
@		EQ 1GM BASE/VIAL	N62724 001			
			DEC 23, 1986			
@		EQ 2GM BASE/VIAL	N62724 002			
			DEC 23, 1986			

CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

	OPHTHOCORT			
+	PARKE DAVIS	10MG/GM;5MG/GM; 10,000 UNITS/GM		**N50201 002**
@		10MG/GM;5MG/GM; 10,000 UNITS/GM		N50201 002

CHLORAMPHENICOL PALMITATE

SUSPENSION; ORAL

	CHLOROMYCETIN PALMITATE		
	PARKE DAVIS	**EQ 150MG BASE/5ML**	**N62301 001**
@		EQ 150MG BASE/5ML	N62301 001

CHLORDIAZEPOXIDE

TABLET; ORAL
LIBRITABS

		ROCHE	10MG	N85481 001
	@		10MG	N85481 001

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT		LEMMON	0.12%	N74522 001 DEC 15, 1995
AT		TEVA	0.12%	N74522 001 DEC 15, 1995

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
NESACAINE-MPF

AP	+	ASTRA	2%	N09435 003
AP	+		2%	N09435 006 MAY 02, 1996
AP	+		3%	N09435 004
AP	+		3%	N09435 007 MAY 02, 1996
	@		2%	N09435 003
	@		3%	N09435 004

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

AA		KV PHARM	4MG	N87164 001
	@		4MG	N87164 001
> DLT >		**KLOROMIN**		
> DLT >	AA	HALSEY	4MG	N83629 001
> ADD >	@		4MG	N83629 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

	@	LEMMON	50MG	N88651 001 MAY 30, 1985

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE

	@	TEVA	50MG	N88651 001 MAY 30, 1985

THALITONE

BX		HORUS THERAP	25MG	N88051 001 NOV 12, 1982
	+		15MG	N19574 001 DEC 20, 1988
BX		MONARCH PHARMS	25MG	N19574 002 FEB 12, 1992
	+		15MG	N19574 001 DEC 20, 1988
	@		25MG	N88051 001 NOV 12, 1982

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA		LEMMON	500MG	N89859 001 MAY 04, 1988
AA		TEVA	500MG	N89859 001 MAY 04, 1988

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB		LEMMON	200MG	N74365 001 FEB 28, 1995
AB			300MG	N74365 002 FEB 28, 1995
AB			400MG	N74365 003 FEB 28, 1995
AB			800MG	N74365 004 FEB 28, 1995
AB		SIDMAK LABS NJ	200MG	N74568 001 FEB 27, 1997
AB			300MG	N74568 002 FEB 27, 1997
AB			400MG	N74568 003 FEB 27, 1997
AB			800MG	N74566 001 FEB 27, 1997

CIMETIDINE

TABLET; ORAL
CIMETIDINE

AB	TEVA	200MG	N74365 001 FEB 28, 1995
AB		300MG	N74365 002 FEB 28, 1995
AB		400MG	N74365 003 FEB 28, 1995
AB		800MG	N74365 004 FEB 28, 1995

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CIMETIDINE HCL

AP	SANOFI	EQ 300MG BASE/2ML	N74296 001 MAR 28, 1997
AP		EQ 300MG BASE/2ML	N74412 001 MAR 28, 1997

SOLUTION; ORAL
CIMETIDINE HCL

AA	PHARM ASSOC	EQ 300MG BASE/5ML	N74553 001 JAN 27, 1997

CLEMASTINE FUMARATE

SYRUP; ORAL
CLEMASTINE FUMARATE

AA	LEMMON	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994
AA	TEVA	EQ 0.5MG BASE/5ML	N73399 001 JUN 30, 1994

TABLET; ORAL
CLEMASTINE FUMARATE

AB	LEMMON	2.68MG	N73283 001 JAN 31, 1992
	@	1.34MG	N73282 001 JAN 31, 1992
AB	TEVA	2.68MG	N73283 001 JAN 31, 1992
	@	1.34MG	N73282 001 JAN 31, 1992

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	QUAD PHARMS	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987
	@	EQ 150MG BASE/ML	N62795 001 DEC 21, 1987

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

AT	LEMMON	EQ 1% BASE	N62930 001 JUN 28, 1989
AT	TEVA	EQ 1% BASE	N62930 001 JUN 28, 1989

CLOBETASOL PROPIONATE

CREAM; TOPICAL
CORMAX

AB	HEALTHPOINT	0.05%	N74220 001 MAY 16, 1997

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL
CLOMIPRAMINE HCL

AB	NOVOPHARM	25MG	N74849 001 APR 04, 1997
AB		50MG	N74849 002 APR 04, 1997
AB		75MG	N74849 003 APR 04, 1997

CLONAZEPAM

TABLET; ORAL
KLONOPIN

+	ROCHE	0.125MG	N17533 005 APR 09, 1997
		0.25MG	N17533 006 APR 09, 1997

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

> DLT >		PHERAZINE W/ CODEINE			
> DLT >	AA	HALSEY	10MG/5ML;6.25MG/5ML	N88739 001	DEC 23, 1988
> DLT >					
> ADD >		@	10MG/5ML;6.25MG/5ML	N88739 001	DEC 23, 1988
> ADD >					

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

	INTAL			
	+ FISONS	0.8MG/INH	N18887 001	DEC 05, 1985
	+ RHONE POULENC RORER	0.8MG/INH	N18887 001	DEC 05, 1985

CAPSULE; INHALATION

	INTAL			
	+ FISONS	20MG	N16990 001	
	+ RHONE POULENC RORER	20MG	N16990 001	

SOLUTION; INHALATION

	INTAL			
AN	+ FISONS	10MG/ML	N18596 001	MAY 28, 1982
AN	+ RHONE POULENC RORER	10MG/ML	N18596 001	MAY 28, 1982

SOLUTION/DROPS; OPHTHALMIC

	OPTICROM			
	@ FISONS	4%	N18155 001	OCT 03, 1984
	@ RHONE POULENC RORER	4%	N18155 001	OCT 03, 1984

SPRAY, METERED; NASAL

	NASALCROM			
	+ FISONS	5.2MG/SPRAY	N18306 001	MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION

> DLT >		COBAVITE		
> DLT >	AP	STERIS	0.1MG/ML	N83013 001

CYANOCOBALAMIN

INJECTABLE; INJECTION

> DLT >		COBAVITE		
> DLT >	AP	STERIS	1MG/ML	N83064 001
> ADD >		@	0.1MG/ML	N83013 001
> ADD >		@	1MG/ML	N83064 001
		CYANOCOBALAMIN		
> DLT >	AP	STERIS	0.1MG/ML	N83120 001
> ADD >		@	0.1MG/ML	N83120 001

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	AK-PENTOLATE			
AT	AKORN	1%	N85555 001	
	@	1%	N85555 001	
	AKPENTOLATE			
AT	AKORN	1%	N40164 001	JAN 13, 1997
AT		2%	N40165 001	JAN 13, 1997
	CYCLOGYL			
AT	+ ALCON	2%	N84108 001	

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

	CYCLOPHOSPHAMIDE			
AP	ASTA	100MG/VIAL	N88371 001	JUL 03, 1986
AP		200MG/VIAL	N88372 001	JUL 03, 1986
AP		500MG/VIAL	N88373 001	JUL 03, 1986
AP		1GM/VIAL	N88374 001	SEP 24, 1986
AP	ELKINS SINN	100MG/VIAL	N88371 001	JUL 03, 1986
AP		200MG/VIAL	N88372 001	JUL 03, 1986
AP		500MG/VIAL	N88373 001	JUL 03, 1986
AP		1GM/VIAL	N88374 001	SEP 24, 1986
> DLT >		CYTOXAN		
> DLT >	AP	+ BRISTOL MYERS SQUIBB	100MG/VIAL	N12142 001

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

> DLT >		CYTOXAN				
> DLT >	AP	+ BRISTOL MYERS SQUIBB	200MG/VIAL	N12142 002		
> DLT >	AP	+	500MG/VIAL	N12142 003		
> DLT >	AP	+	1GM/VIAL	N12142 004		
				AUG 30, 1982		
> DLT >				N12142 005		
> DLT >	AP	+	2GM/VIAL	AUG 30, 1982		
> DLT >						
> ADD >		@	100MG/VIAL	N12142 001		
> ADD >		@	200MG/VIAL	N12142 002		
> ADD >		@	500MG/VIAL	N12142 003		
> ADD >		@	1GM/VIAL	N12142 004		
				AUG 30, 1982		
> ADD >						
> ADD >		@	2GM/VIAL	N12142 005		
> ADD >				AUG 30, 1982		

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

		CYPROHEPTADINE HCL		
> DLT >	AA	HALSEY	4MG	N89057 001
				JUL 03, 1986
> DLT >				
> ADD >		@	4MG	N89057 001
				JUL 03, 1986
> ADD >				

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

		CERUBIDINE		
	AP	RHONE POULENC RORER	EQ 20MG BASE/VIAL	N61876 001
		@	EQ 20MG BASE/VIAL	N61876 001
	AP	+ WYETH AYERST	EQ 20MG BASE/VIAL	N50484 001
		@	EQ 20MG BASE/VIAL	N50484 001
		DAUNORUBICIN HCL		
	AP	BEDFORD	EQ 20MG BASE/VIAL	N64103 001
				FEB 03, 1995
		+	EQ 20MG BASE/VIAL	N64103 001
				FEB 03, 1995

DELAVIRDINE MESYLATE

TABLET; ORAL

		RESCRIPTOR		
		+ PHARMACIA AND UPJOHN	100MG	N20705 001
				APR 04, 1997

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

		DESIPRAMINE HCL		
> ADD >	AB	SIDMAK LABS NJ	100MG	N71803 001
				MAY 29, 1997
> ADD >				
> ADD >	AB		150MG	N71804 001
				MAY 29, 1997
> ADD >				

DEXAMETHASONE SODIUM PHOSPHATE

CREAM; TOPICAL

		DECADRON		
		+ MERCK SHARP DOHME	EQ 0.1% PHOSPHATE	N11983 002
		@	EQ 0.1% PHOSPHATE	N11983 002

INJECTABLE; INJECTION

		DEXAMETHASONE SODIUM PHOSPHATE		
> DLT >	AP	STERIS	EQ 4MG PHOSPHATE/ML	N84355 001
> ADD >		@	EQ 4MG PHOSPHATE/ML	N84355 001

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

		POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER		
> DLT >		MCGAW	5GM/100ML;37MG/100ML	N19699 001
				SEP 29, 1989
> DLT >				
> ADD >		@	5GM/100ML;37MG/100ML	N19699 001
				SEP 29, 1989
> ADD >				
		POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER		
> DLT >	AP	MCGAW	5GM/100ML;75MG/100ML	N19699 002
				SEP 29, 1989
> DLT >				
> ADD >		@	5GM/100ML;75MG/100ML	N19699 002
				SEP 29, 1989
> ADD >				
		POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER		
> DLT >		MCGAW	5GM/100ML;110MG/100ML	N19699 003
				SEP 29, 1989
> DLT >				
> ADD >		@	5GM/100ML;110MG/100ML	N19699 003
				SEP 29, 1989
> ADD >				
		POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER		
> DLT >		MCGAW	5GM/100ML;220MG/100ML	N19699 005
				SEP 29, 1989
> DLT >				

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER

> ADD >		@ MCGAW	5GM/100ML;220MG/100ML	N19699 005
> ADD >				SEP 29, 1989

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

> DLT >	AP	MCGAW	5GM/100ML;900MG/100ML	N18026 001
> ADD >		@	5GM/100ML;900MG/100ML	N18026 001

DEXTROTHYROXINE SODIUM

TABLET; ORAL
CHOLOXIN

		KNOLL PHARM	1MG	N12302 005
		@	1MG	N12302 005

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

> DLT >	AP	STERIS	5MG/ML	N70912 001
> DLT >				AUG 28, 1986
> ADD >		@	5MG/ML	N70912 001
> ADD >				AUG 28, 1986

TABLET; ORAL
DIAZEPAM

> DLT >	AB	HALSEY	2MG	N70987 001
> DLT >				AUG 15, 1986
> DLT >	AB		5MG	N70996 001
> DLT >				AUG 15, 1986
> DLT >	AB		10MG	N70956 001
> DLT >				AUG 15, 1986
> ADD >		@	2MG	N70987 001
> ADD >				AUG 15, 1986
> ADD >		@	5MG	N70996 001
> ADD >				AUG 15, 1986
> ADD >		@	10MG	N70956 001
> ADD >				AUG 15, 1986

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL
DICYCLOMINE HCL

AB		WEST WARD	10MG	N40204 001
				FEB 28, 1997

DIETHYLSTILBESTROL

TABLET; ORAL
DIETHYLSTILBESTROL

		LILLY	1MG	N04041 004
		*	5MG	N04041 005
		@	1MG	N04041 004
		@	5MG	N04041 005

STILBESTROL

		TABLICAPS	0.5MG	N83004 001
		@	0.5MG	N83004 001

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

> ADD >	AB	MYLAN	60MG	N74910 001
> ADD >				MAY 02, 1997
> ADD >	AB		90MG	N74910 002
> ADD >				MAY 02, 1997
> ADD >	AB		120MG	N74910 003
> ADD >				MAY 02, 1997

DIMENHYDRINATE

INJECTABLE; INJECTION
DIMENHYDRINATE

	AP	ELKINS SINN	50MG/ML	N84767 001
		@	50MG/ML	N84767 001

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

> DLT >	AP	STERIS	10MG/ML	N83533 001
> ADD >		@	10MG/ML	N83533 001

DIPYRIDAMOLE

TABLET; ORAL

		DIPYRIDAMOLE			
>ADD< >ADD<	**AB**	CHELSEA LABS	**50MG**	**N87160 001** JUN 07, 1996	

DOXAZOSIN MESYLATE

TABLET; ORAL

	CARDURA			
	PFIZER	EQ 1MG BASE	N19668 001 NOV 02, 1990	
+		EQ 8MG BASE	N19668 004 NOV 02, 1990	
+		EQ 1MG BASE	N19668 001 NOV 02, 1990	
		EQ 8MG BASE	N19668 004 NOV 02, 1990	

ECONAZOLE NITRATE

CREAM; TOPICAL

SPECTAZOLE			
+	J AND J	1%	N18751 001 DEC 23, 1982
+	JOHNSON RW	1%	N18751 001 DEC 23, 1982

ERYTHROMYCIN

SOLUTION; TOPICAL

	ERYTHROMYCIN			
AT	STIEFEL	**2%**	**N64127 001** FEB 14, 1997	

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-21

	ALESSE			
+	WYETH AYERST	0.02MG;0.1MG	N20683 001 MAR 27, 1997	

TABLET; ORAL-28

ALESSE			
	WYETH AYERST	0.02MG;0.1MG	N20683 002 MAR 27, 1997

ETODOLAC

CAPSULE; ORAL

		ETODOLAC			
>ADD< >ADD< >ADD<	**AB**	MYLAN	**200MG**		**N74932 001** MAY 16, 1997
>ADD< >ADD<	**AB**		**300MG**		**N74932 002** MAY 16, 1997
		LODINE			
>ADD< >ADD< >ADD<	**AB**	WYETH AYERST	**200MG**		**N18922 002** JAN 31, 1991
>ADD< >ADD<	**AB**	+	**300MG**		**N18922 003** JAN 31, 1991

TABLET; ORAL

	ETODOLAC			
AB	EON	**400MG**		**N74903 001** APR 11, 1997
AB	INVAMED	**400MG**		**N74846 001** FEB 28, 1997
AB	PUREPAC PHARM	**400MG**		**N74819 001** FEB 28, 1997
AB	ROYCE LABS	**400MG**		**N74892 001** APR 16, 1997
AB	ZENITH GOLDLINE	**400MG**		**N74883 001** FEB 28, 1997
	LODINE			
AB	WYETH AYERST	**400MG**		**N18922 004** JUL 29, 1993

ETOPOSIDE

INJECTABLE; INJECTION

	ETOPOSIDE			
AP	IMMUNEX	**20MG/ML**		**N74513 001** MAR 14, 1996
AP	SUPERGEN	**20MG/ML**		**N74513 001** MAR 14, 1996

FLECAINIDE ACETATE

TABLET; ORAL

	TAMBOCOR			
>ADD< >ADD< >DLT<	@ 3N	50MG		**N18830 004** AUG 23, 1988
>DLT< >DLT< >DLT<	@	100MG		**N18830 001** OCT 31, 1985

FLECAINIDE ACETATE

TABLET; ORAL
TAMBOCOR

>ADD>	@ 3M	150MG	N18830 003	
>DLT>			JUN 03, 1988	
>ADD>		50MG	N18830 004	
>ADD>			AUG 23, 1988	
>ADD>		100MG	N18830 001	
>ADD>			OCT 31, 1985	
>ADD>	+	150MG	N18830 003	
>ADD>			JUN 03, 1988	

FLUCONAZOLE

INJECTABLE; INJECTION
DIFLUCAN

>ADD>	+ PFIZER	200MG/100ML	N19950 001	
>DLT>			JAN 29, 1990	

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

>ADD>	+ PFIZER	200MG/100ML	N19950 003	
>DLT>			SEP 29, 1992	
>ADD>	@	2MG/ML	N19950 005	
>DLT>			JUL 08, 1994	

DIFLUCAN IN SODIUM CHLORIDE 0.9%

>ADD>	+ PFIZER	200MG/100ML	N19950 001	
>DLT>			JAN 29, 1990	

DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>ADD>	+ PFIZER	200MG/100ML	N19950 002	
>DLT>			JAN 29, 1990	
>ADD>	@	2MG/ML	N19950 004	
>DLT>			JUL 08, 1994	

FLUNISOLIDE

SPRAY, METERED; NASAL
NASALIDE

>ADD>	BX	+ DURA	0.025MG/SPRAY	N18148 001	
>DLT>	BX	+ SYNTEX	0.025MG/SPRAY	N18148 001	

NASAREL

>ADD>	BX	+ DURA	0.025MG/SPRAY	N20409 001	
>ADD>				MAR 08, 1995	
>DLT>	BX	+ SYNTEX	0.025MG/SPRAY	N20409 001	
>DLT>				MAR 08, 1995	

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
SYNALAR

>ADD>	AT	+ MEDICIS	0.01%	N12787 004	
>ADD>	AT	+	0.025%	N12787 002	
>ADD>	AT	+	0.025%	N12787 005	
>DLT>	AT	+ SYNTEX	0.01%	N12787 004	
>DLT>	AT	+	0.025%	N12787 002	
>DLT>	AT	+	0.025%	N12787 005	

SYNALAR-HP

>ADD>		+ MEDICIS	0.2%	N16161 002
>DLT>		+ SYNTEX	0.2%	N16161 002

OINTMENT; TOPICAL
SYNALAR

>ADD>	AT	+ MEDICIS	0.025%	N13960 001	
>DLT>	AT	+ SYNTEX	0.025%	N13960 001	

SOLUTION; TOPICAL
SYNALAR

>ADD>	AT	+ MEDICIS	0.01%	N15296 001	
>DLT>	AT	+ SYNTEX	0.01%	N15296 001	

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM; TOPICAL
NEO-SYNALAR

>ADD>	+ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001
>DLT>	+ SYNTEX	0.025%;EQ 3.5MG BASE/GM	N60700 001

FLUOCINONIDE

CREAM; TOPICAL
LIDEX

>ADD>	AB	+ MEDICIS	0.05%	N16908 002	
>DLT>	AB	+ SYNTEX	0.05%	N16908 002	

LIDEX-E

>ADD>	AB	MEDICIS	0.05%	N16908 003	
>DLT>	AB	SYNTEX	0.05%	N16908 003	

GEL; TOPICAL
LIDEX

>ADD>	AB	+ MEDICIS	0.05%	N17373 001	
>DLT>	AB	+ SYNTEX	0.05%	N17373 001	

OINTMENT; TOPICAL
LIDEX

>ADD>	AB	+ MEDICIS	0.05%	N16909 002

FLUOCINONIDE

OINTMENT; TOPICAL

		LIDEX				
> DLT >	AB	+ SYNTEX	0.05%	N16909 002		

SOLUTION; TOPICAL

		LIDEX				
> ADD >	AT	+ MEDICIS	0.05%	N18849 001 APR 06, 1984		
> ADD >						
> DLT >	AT	+ SYNTEX	0.05%	N18849 001 APR 06, 1984		
> DLT >						

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL

		FLURAZEPAM HCL				
> DLT >	AB	HALSEY	15MG	N71808 001 JAN 07, 1988		
> DLT >						
> DLT >	AB		30MG	N71809 001 JAN 07, 1988		
> DLT >						
> ADD >		@	15MG	N71808 001 JAN 07, 1988		
> ADD >						
> ADD >		@	30MG	N71809 001 JAN 07, 1988		
> ADD >						

FLURBIPROFEN

TABLET; ORAL

		FLURBIPROFEN				
	AB	SIDMAK LABS NJ	50MG	N74647 001 APR 01, 1997		
	AB		100MG	N74647 002 APR 01, 1997		
> ADD >	AB	WARNER CHILCOTT	100MG	N74560 002 MAY 16, 1997		
> ADD >						

GLIPIZIDE

TABLET; ORAL

		GLIPIZIDE				
	AB	SIDMAK LABS NJ	5MG	N74619 001 APR 04, 1997		
	AB		10MG	N74619 002 APR 04, 1997		

GLUTETHIMIDE

TABLET; ORAL

		GLUTETHIMIDE				
> DLT >	AA	HALSEY	500MG	N89459 001 OCT 10, 1986		
> DLT >						
> ADD >		@	500MG	N89459 001 OCT 10, 1986		
> ADD >						

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

		GRIFULVIN V				
		J AND J	125MG/5ML	N62483 001 JAN 26, 1984		
		JOHNSON RW	125MG/5ML	N62483 001 JAN 26, 1984		

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

		GUANFACINE HCL				
	AB	AMIDE PHARM	EQ 1MG BASE	N74673 001 FEB 28, 1997		
	AB		EQ 2MG BASE	N74673 002 FEB 28, 1997		
	AB	MYLAN	EQ 1MG BASE	N74796 001 JAN 27, 1997		
	AB		EQ 2MG BASE	N74796 002 JAN 27, 1997		

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

		HALDOL				
> ADD >		+ JOHNSON RW	EQ 50MG BASE/ML	N18701 001 JAN 14, 1986		
> ADD >						
> ADD >		+	EQ 100MG BASE/ML	N18701 002 JAN 31, 1997		
> ADD >						
> DLT >		HALDOL DECANOATE 100				
> DLT >		+ JOHNSON RW	EQ 100MG BASE/ML	N18701 002 OCT 31, 1989		
> DLT >						
> DLT >		HALDOL DECANOATE 50				
> DLT >		+ JOHNSON RW	EQ 50MG BASE/ML	N18701 001 JAN 14, 1986		
> DLT >						

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEP FLUSH KIT IN PLASTIC CONTAINER			
AP	FUJISAWA	**10 UNITS/ML**	**N17029 017**	
			DEC 05, 1985	
AP		**100 UNITS/ML**	**N17029 018**	
			DEC 05, 1985	
	@	10 UNITS/ML	N17029 017	
			DEC 05, 1985	
	@	100 UNITS/ML	N17029 018	
			DEC 05, 1985	
	HEPARIN SODIUM			
AP	FUJISAWA	**20,000 UNITS/ML**	**N17029 004**	
AP	STERIS	**1,000 UNITS/ML**	**N17064 002**	
	@	1,000 UNITS/ML	N17064 002	

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

		HYDROPANE			
> DLT >	**AA**	HALSEY	**1.5MG/5ML;5MG/5ML**	**N88066 001**	
> DLT >				JUN 28, 1985	
> ADD >		@	1.5MG/5ML;5MG/5ML	N88066 001	
> ADD >				JUN 28, 1985	

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

		HYDRALAZINE HCL			
> DLT >	**AA**	HALSEY	**25MG**	**N89130 001**	
> DLT >				JAN 15, 1986	
> DLT >	**AA**		**100MG**	**N89178 001**	
> DLT >				JAN 15, 1986	
> ADD >		@	25MG	N89130 001	
> ADD >				JAN 15, 1986	
> ADD >		@	100MG	N89178 001	
> ADD >				JAN 15, 1986	

HYDROCORTISONE

CREAM; TOPICAL

	DERMACORT			
AT	MONARCH PHARMS	**1%**	**N83011 002**	
AT	SOLVAY	**1%**	**N83011 002**	
	PROCTOCORT			
AT	MONARCH PHARMS	**1%**	**N83011 001**	

HYDROCORTISONE

CREAM; TOPICAL

		PROCTOCORT			
	AT	SOLVAY	**1%**		**N83011 001**
		SYNACORT			
> ADD >	**AT**	MEDICIS	**1%**		**N87458 001**
> ADD >	**AT**		**2.5%**		**N87457 001**
> ADD >		@	0.5%		N87459 001
> DLT >	**AT**	SYNTEX	**1%**		**N87458 001**
> DLT >	**AT**		**2.5%**		**N87457 001**
> DLT >		@	0.5%		N87459 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

		CORTISPORIN			
> DLT >	**AT**	+ GLAXO WELLCOME	**1%;EQ 3.5MG BASE/ML;**		
> DLT >			**10,000 UNITS/ML**		**N50479 001**
> ADD >	**AT**	+ MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML;**		
> ADD >			**10,000 UNITS/ML**		**N50479 001**
> DLT >		**OTOCORT**			
> DLT >	**AT**	STERIS	**1%;EQ 3.5MG BASE/ML;**		
> DLT >			**10,000 UNITS/ML**		**N60730 002**
> ADD >		@	1%;EQ 3.5MG BASE/ML;		
> ADD >			10,000 UNITS/ML		N60730 002

SUSPENSION/DROPS; OTIC

		OTOCORT			
> DLT >	**AT**	STERIS	**1%;EQ 3.5MG BASE/ML;**		
> DLT >			**10,000 UNITS/ML**		**N62521 001**
> DLT >					JUL 11, 1985
> ADD >		@	1%;EQ 3.5MG BASE/ML;		
> ADD >			10,000 UNITS/ML		N62521 001
> ADD >					JUL 11, 1985
		PEDIOTIC			
> DLT >	**AT**	GLAXO WELLCOME	**1%;EQ 3.5MG BASE/ML;**		
> DLT >			**10,000 UNITS/ML**		**N62822 001**
> DLT >					SEP 29, 1987
> ADD >	**AT**	MONARCH PHARMS	**1%;EQ 3.5MG BASE/ML;**		
> ADD >			**10,000 UNITS/ML**		**N62822 001**
> ADD >					SEP 29, 1987

HYDROCORTISONE; UREA

CREAM; TOPICAL

	ALPHADERM		
	@ BIOGLAN	1%;10%	N86008 001

HYDROCORTISONE; UREA

CREAM; TOPICAL

	ALPHADERM			
	@ VIVAN	1%;10%		N86008 001

HYDROCORTISONE ACETATE

CREAM; TOPICAL

	HEMSOL-HC			
>DLT>	AT ABLE	1%		N81274 001
>DLT>				JUN 19, 1992
>ADD>	+	1%		N81274 001
>ADD>				JUN 19, 1992
>DLT>	HYDROCORTISONE ACETATE			
>DLT>	AT + PUREPAC PHARM	1%		N86052 001
>ADD>	@	1%		N86052 001

INJECTABLE; INJECTION

	HYDROCORTISONE ACETATE			
>DLT>	BP STERIS	25MG/ML		N83759 001
>DLT>	BP	50MG/ML		N83759 002
>ADD>	@	25MG/ML		N83759 001
>ADD>	@	50MG/ML		N83759 002

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM; TOPICAL

>DLT>	CORTISPORIN			
>DLT>	+ GLAXO WELLCOME	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50218 001
>DLT>				AUG 09, 1985
>ADD>	+ MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM		N50218 001
>ADD>				AUG 09, 1985

HYDROCORTISONE BUTEPRATE

CREAM; TOPICAL

	PANDEL			
	+ SAVAGE LABS	0.1%		N20453 001
				FEB 28, 1997

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

	HYDROCORTISONE SODIUM SUCCINATE			
AP	ELKINS SINN	EQ 1GM BASE/VIAL		N87569 001
	@	EQ 1GM BASE/VIAL		N87569 001

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

	HYDROXYZINE HCL			
>DLT>	AB HALSEY	25MG		N89117 001
>DLT>				MAY 02, 1988
>ADD>	@	25MG		N89117 001
>ADD>				MAY 02, 1988
	AB KV PHARM	10MG		N87819 001
				JUN 23, 1982
	AB	25MG		N87820 001
				JUN 23, 1982
	AB	50MG		N87821 001
				JUN 23, 1982
	AB	100MG		N87822 001
				JUN 23, 1982
	@	10MG		N87819 001
				JUN 23, 1982
	@	25MG		N87820 001
				JUN 23, 1982
	@	50MG		N87821 001
				JUN 23, 1982
	@	100MG		N87822 001
				JUN 23, 1982

HYDROXYZINE PAMOATE

CAPSULE; ORAL

	HY-PAM			
AB	EON	EQ 25MG HCL		N87479 001
	HYDROXYZINE PAMOATE			
AB	EON	EQ 25MG HCL		N87479 001

IBUPROFEN

SUSPENSION; ORAL

	IBU			
>DLT>				
>DLT>	BX KNOLL PHARM	100MG/5ML		N19784 001
>DLT>				DEC 18, 1989

IBUPROFEN

SUSPENSION; ORAL

> ADD >		IBU			
> ADD >		@ KNOLL PHARM	100MG/5ML	N19784 001	
> ADD >				DEC 18, 1989	

TABLET; ORAL

IBUPROFEN

> DLT >	AB	FUREPAC PHARM	800MG	N71964 001	
> DLT >				FEB 01, 1988	
> ADD >		@	800MG	N71964 001	
> ADD >				FEB 01, 1988	

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDAMYCIN PFS

		+ PHARMACIA AND UPJOHN	1MG/ML	N50734 001	
				FEB 17, 1997	

IFOSFAMIDE

> DLT >		INJECTABLE; INJECTION			
> DLT >		IFEX			
> DLT >		+ BRISTOL MYERS SQUIBB	1GM/VIAL	N19763 001	
> DLT >				DEC 30, 1988	
> DLT >		+	3GM/VIAL	N19763 002	
> DLT >				DEC 30, 1988	
> ADD >		@	1GM/VIAL	N19763 001	
> ADD >				DEC 30, 1988	
> ADD >		@	3GM/VIAL	N19763 002	
> ADD >				DEC 30, 1988	

> ADD > IFOSFAMIDE; MESNA

> ADD >		INJECTABLE; INJECTION			
> ADD >		IFEX/MESNEX KIT			
> ADD >		+ BRISTOL MYERS SQUIBB	1GM/VIAL;100MG/ML	N19763 003	
> ADD >				OCT 10, 1992	
> ADD >		+	3GM/VIAL;100MG/ML	N19763 004	
> ADD >				OCT 10, 1992	

IMIQUIMOD

CREAM; TOPICAL

ALDARA

		+ 3M	5%	N20723 001	
				FEB 27, 1997	

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

	AB	MYLAN	1.25MG	N74461 002	
				MAR 26, 1997	
	AB	NOVOPHARM	1.25MG	N74665 001	
				APR 04, 1997	
	AB		2.5MG	N74665 002	
				APR 04, 1997	

INDOCYANINE GREEN

INJECTABLE; INJECTION

CARDIO-GREEN

> ADD >		+ AKORN	25MG/VIAL	N11525 001	
> ADD >		+	50MG/VIAL	N11525 002	
> DLT >		+ BECTON DICKINSON	25MG/VIAL	N11525 001	
> DLT >		+	50MG/VIAL	N11525 002	

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-250

	AP	FUJISAWA	51%	N74679 001	
				APR 02, 1997	

IOPAMIDOL-300

	AP	ABBOTT	61%	N74638 001	
				APR 30, 1997	
	AP	FUJISAWA	61%	N74679 002	
				APR 02, 1997	

IOPAMIDOL-300 IN PLASTIC CONTAINER

	AP	ABBOTT	61%	N74637 001	
				APR 03, 1997	

IOPAMIDOL-370

	AP	FUJISAWA	76%	N74679 003	
				APR 02, 1997	

ISOVUE-250

	AP	+ BRACCO	51%	N18735 007	
				JUL 06, 1992	

IOPAMIDOL

INJECTABLE; INJECTION
ISOVUE-250

AP	+ BRACCO	51%	N20327 002	> ADD >	
			OCT 12, 1994	> ADD	

IPRATROPIUM BROMIDE

SOLUTION; INHALATION
ATROVENT

AN	+ BOEHRINGER INGELHEIM	0.02%	N20228 001		
			SEP 29, 1993	> DLT >	

IPRATROPIUM BROMIDE

AN	DEY	0.02%	N74755 001	> DLT >	
			JAN 10, 1997	> DLT >	

ISONIAZID

SYRUP; ORAL
ISONIAZID

AA	CAROLINA MEDCL	50MG/5ML	N88235 001	> ADD >	
			NOV 10, 1983	> ADD >	
	+	50MG/5ML	N88235 001	> ADD >	
			NOV 10, 1983		

LANIAZID

AA	LANNETT	50MG/5ML	N89243 001		
			FEB 03, 1986		
	@	50MG/5ML	N89243 001		
			FEB 03, 1986		

ITRACONAZOLE

SOLUTION; ORAL
SPORANOX

	+ JANSSEN	10MG/ML	N20657 001		
			FEB 21, 1997		

KETOROLAC TROMETHAMINE

TABLET; ORAL
KETOROLAC TROMETHAMINE

> ADD >					
> ADD >	AB	LEMMON	10MG	N74754 001	
> ADD >				MAY 16, 1997	

KETOROLAC TROMETHAMINE

TABLET; ORAL
KETOROLAC TROMETHAMINE

				> ADD >	
	AB	MYLAN	10MG	> ADD >	N74761 001
				> ADD	MAY 16, 1997

TORADOL

				> ADD >	
	AB + SYNTEX	10MG		> ADD >	N19645 001
					DEC 20, 1991

LANSOPRAZOLE

CAPSULE, DELAYED REL GRANULES; ORAL
PREVACID

> DLT >					
> DLT >					
> DLT >		TAP HOLDINGS	15MG		N20406 001
> DLT >					MAY 10, 1995
> DLT >		+	30MG		N20406 002
> DLT >					MAY 10, 1995

CAPSULE, DELAYED REL PELLETS; ORAL
PREVACID

> ADD >					
> ADD >					
> ADD >		TAP HOLDINGS	15MG		N20406 001
> ADD >					MAY 10, 1995
> ADD >		+	30MG		N20406 002
> ADD >					MAY 10, 1995

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION
LEUCOVORIN CALCIUM

AP	PHARMACHEMIE	EQ 50MG BASE/VIAL	N89628 001	
			APR 17, 1997	
AP		EQ 100MG BASE/VIAL	N89915 001	
			APR 17, 1997	

TABLET; ORAL
LEUCOVORIN CALCIUM

AB	PHARMACHEMIE	EQ 5MG BASE	N73099 001	
			MAR 28, 1997	
AB		EQ 25MG BASE	N73101 001	
			MAR 28, 1997	

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LUPRON DEPOT-3				
	+ TAP HOLDINGS	11.25MG/VIAL	N20708 001 MAR 07, 1997		
>ADD>	LUPRON DEPOT-4				
>ADD>	+ TAP HOLDINGS	30MG/VIAL	N20517 002 MAY 30, 1997		
>ADD>					

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHOBID			
SOLVAY	300MG	N18027 001	
+	300MG	N18027 001	

LORAZEPAM

SOLUTION; ORAL

LORAZEPAM			
+ ROXANE	0.5MG/5ML	N74648 001 MAR 18, 1997	

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HCL				
AA KV PHARM	12.5MG	N85524 001		
AA	25MG	N85523 001		
@	12.5MG	N85524 001		
@	25MG	N85523 001		
AA VINTAGE PHARMS	12.5MG	N40179 001 JAN 30, 1997		
AA	25MG	N40179 002 JAN 30, 1997		

MENOTROPINS (FSH;LH)

INJECTABLE; INJECTION

HUMEGON					
AB * ORGANON	75 IU/VIAL;75 IU/VIAL	N20328 001 SEP 01, 1994			
AB	75 IU/VIAL;75 IU/VIAL	N20328 001 SEP 01, 1994			
			>DLT>	MENOTROPINS (FSH;LH)	
				INJECTABLE; INJECTION	
				HUMEGON	
			AB + ORGANON	150 IU/VIAL;150 IU/VIAL	N20328 002 SEP 01, 1994
			AB	150 IU/VIAL;150 IU/VIAL	N20328 002 SEP 01, 1994
			>DLT>	REPRONAL	
			>DLT> AB	FERRING 75 IU/VIAL;75 IU/VIAL	N73598 001 JAN 30, 1997
			>DLT>		
			>DLT> AB	150 IU/VIAL;150 IU/VIAL	N73599 001 JAN 30, 1997
			>DLT>		

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL				
>ADD> AP MALLINCKRODT	10MG/ML	N40163 001 MAY 12, 1997		
>ADD>				

TABLET; ORAL

MEPERIDINE HCL			
AA ROXANE	50MG	N40110 001 MAR 12, 1997	
AA	100MG	N40110 002 MAR 12, 1997	

METAPROTERENOL SULFATE

SYRUP; ORAL

METAPROTERENOL SULFATE			
AA JVL	10MG/5ML	N74702 001 MAR 24, 1997	
AA MORTON GROVE	10MG/5ML	N71656 001 OCT 13, 1987	
@	10MG/5ML	N71656 001 OCT 13, 1987	

METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLUCOPHAGE			
BRISTOL MYERS SQUIBB	500MG	N20357 001 DEC 29, 1994	

METFORMIN HYDROCHLORIDE

TABLET; ORAL
GLUCOPHAGE

+	BRISTOL MYERS SQUIBB	850MG	N20357 002	DEC 29, 1994
		500MG	N20357 001	MAR 03, 1995
+		850MG	N20357 002	MAR 03, 1995

METHACHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; INHALATION
PROVOCHOLINE

	METHAPHARM	100MG/VIAL	N19193 001 OCT 31, 1986
	ROCHE	100MG/VIAL	N19193 001 OCT 31, 1986

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

> DLT >	AA	PUREPAC PHARM	500MG	N85718 001
> DLT >	AA		750MG	N85718 002
> ADD >	@		500MG	N85718 001
> ADD >	@		750MG	N85718 002

METHOTREXATE SODIUM

INJECTABLE; INJECTION
MEXATE-AQ PRESERVED

AP	BRISTOL MYERS	EQ 25MG BASE/ML	N89887 001 APR 14, 1989
@	BRISTOL MYERS SQUIBB	EQ 25MG BASE/ML	N89887 001 APR 14, 1989

METHOXSALEN

> ADD > CAPSULE; ORAL
> ADD > OXSORALEN-ULTRA
> ADD > + ICN 10MG N19600 001 OCT 30, 1986
> ADD >

> DLT > CAPSULE, LIQUID FILLED; ORAL
> DLT > OXSORALEN-ULTRA
> DLT > + ICN 10MG N19600 001 OCT 30, 1986
> DLT >

METHYLDOPA

TABLET; ORAL
METHYLDOPA

> DLT >	AB	HALSEY	125MG	N71751 001 MAR 28, 1988
> DLT >	AB		250MG	N71752 001 MAR 28, 1988
> ADD >	@		125MG	N71751 001 MAR 28, 1988
> ADD >	@		250MG	N71752 001 MAR 28, 1988
> DLT >	AB	PUREPAC PHARM	125MG	N70749 001 FEB 07, 1986
> DLT >	AB		250MG	N70750 001 FEB 07, 1986
> DLT >	AB		500MG	N70452 001 FEB 07, 1986
> ADD >	@		125MG	N70749 001 FEB 07, 1986
> ADD >	@		250MG	N70750 001 FEB 07, 1986
> ADD >	@		500MG	N70452 001 FEB 07, 1986

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

AP	FAULDING	EQ 5MG BASE/ML	N71990 001 JAN 18, 1989
@		EQ 5MG BASE/ML	N71990 001 JAN 18, 1989

TABLET; ORAL
METOCLOPRAMIDE HCL

AB	MUTUAL PHARM	EQ 5MG BASE	N71536 002 JAN 16, 1997

METOLAZONE

TABLET; ORAL

	MYKROX			
	MEDEVA	0.5MG	N19532 001	
			OCT 30, 1987	
+		0.5MG	N19532 001	
			OCT 30, 1987	

METRONIDAZOLE

GEL; VAGINAL

	METROGEL-VAGINAL			
+	3M	0.75%	N20208 001	
			AUG 17, 1992	
+	CURATEK	0.75%	N20208 001	
			AUG 17, 1992	

INJECTABLE; INJECTION

		METRONIDAZOLE			
> DLT >	AP	STERIS	500MG/100ML	N70042 001	
> DLT >				DEC 20, 1984	
> ADD >	@		500MG/100ML	N70042 001	
> ADD >				DEC 20, 1984	

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

		MEXILETINE HCL			
AB		WATSON LABS	150MG	N74711 001	> DLT >
				FEB 26, 1997	> DLT >
AB			200MG	N74711 002	> ADD >
				FEB 26, 1997	> ADD >
AB			250MG	N74711 003	> ADD >
				FEB 26, 1997	> ADD >

MICONAZOLE NITRATE

LOTION; TOPICAL

	MONISTAT-DERM		
	@ J AND J	2%	N17739 001
	@ JOHNSON RW	2%	N17739 001

MIRTAZAPINE

TABLET; ORAL

	REMERON		
+	ORGANON	30MG	N20415 002
			JUN 14, 1996
		30MG	N20415 002
			JUN 14, 1996
+		45MG	N20415 003
			MAR 17, 1997

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

		PENTAZOCINE AND NALOXONE HYDROCHLORIDES		
AB		ROYCE LABS	EQ 0.5MG BASE; EQ 50MG BASE	N74736 001
				JAN 21, 1997
		TALWIN NX		
AB	+	SANOFI WINTHROP	EQ 0.5MG BASE; EQ 50MG BASE	N18733 001
				DEC 16, 1982

NANDROLONE DECANOATE

INJECTABLE; INJECTION

		NANDROLONE DECANOATE			
> DLT >	AQ	STERIS	50MG/ML	N87598 001	
> DLT >				OCT 06, 1983	
> DLT >	AQ		100MG/ML	N87599 001	
> DLT >				OCT 06, 1983	
> ADD >		@	50MG/ML	N87598 001	
> ADD >				OCT 06, 1983	
> ADD >		@	100MG/ML	N87599 001	
> ADD >				OCT 06, 1983	

NEDOCROMIL SODIUM

AEROSOL, METERED; INHALATION

	TILADE		
+	FISONS	1.75MG/INH	N19660 001
			DEC 30, 1992
+	RHONE POULENC RORER	1.75MG/INH	N19660 001
			DEC 30, 1992

NELFINAVIR MESYLATE

POWDER FOR RECONSTITUTION; ORAL
VIRACEPT
+ AGOURON — EQ 50MG BASE/SCOOPFUL — N20778 001 MAR 14, 1997

TABLET; ORAL
VIRACEPT
+ AGOURON — EQ 250MG BASE — N20779 001 MAR 14, 1997

NEOMYCIN SULFATE

POWDER; FOR RX COMPOUNDING
NEO-RX
AA PHARMA TEK — 100% — N61579 001
100% — N61579 001

NEOMYCIN SULFATE
AA PADDOCK — 100% — N62385 001 JUN 01, 1982

NIACIN

TABLET; ORAL
NIACIN
>DLT< AA HALSEY — 500MG — N83453 001
>ADD< @ — 500MG — N83453 001

NICOTINE

>ADD< INHALANT; INHALATION
>ADD< NICOTROL
>ADD< + PHARMACIA AND UPJOHN — 4MG/CARTRIDGE — N20714 001 MAY 02, 1997

ONDANSETRON HYDROCHLORIDE

SOLUTION; ORAL
ZOFRAN
+ GLAXO WELLCOME — EQ 4MG BASE/5ML — N20605 001 JAN 24, 1997

OXACILLIN SODIUM

CAPSULE; ORAL
BACTOCILL
AB SMITHKLINE BEECHAM — EQ 250MG BASE — N61336 001
AB + EQ 250MG BASE — N61336 001

OXACILLIN SODIUM
>DLT< AB APOTHECON — EQ 250MG BASE — N61450 002
>DLT< AB + EQ 500MG BASE — N61450 001
>ADD< @ — EQ 250MG BASE — N61450 002
>ADD< @ — EQ 500MG BASE — N61450 001

OXYBUTYNIN CHLORIDE

SYRUP; ORAL
OXYBUTYNIN CHLORIDE
AA MORTON GROVE — 5MG/5ML — N74868 001 FEB 12, 1997

OXYCODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
+ PURDUE FREDERICK — 10MG — N20553 001 DEC 12, 1995
+ — 20MG — N20553 002 DEC 12, 1995
+ — 40MG — N20553 003 DEC 12, 1995
+ PURDUE PHARMA — 10MG — N20553 001 DEC 12, 1995
+ — 20MG — N20553 002 DEC 12, 1995
+ — 40MG — N20553 003 DEC 12, 1995
+ — 80MG — N20553 004 JAN 06, 1997

OXYTOCIN

>DLT< SOLUTION; NASAL
>DLT< SYNTOCINON
>DLT< + NOVARTIS — 40 USP UNITS/ML — N12285 001
>ADD< @ — 40 USP UNITS/ML — N12285 001

PERINDOPRIL ERBUMINE

TABLET; ORAL
ACEON

> DLT >		RHONE POULENC RORER	2MG	N20184 001
> DLT >				DEC 30, 1993
> DLT >			4MG	N20184 002
> DLT >				DEC 30, 1993
> DLT >	+		8MG	N20184 003
> DLT >				DEC 30, 1993
> ADD >	@		2MG	N20184 001
> ADD >				DEC 30, 1993
> ADD >	@		4MG	N20184 002
> ADD >				DEC 30, 1993
> ADD >	@		8MG	N20184 003
> ADD >				DEC 30, 1993

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL
PHENDIMETRAZINE TARTRATE

BC		GRAHAM DM	105MG	N87214 001
				MAY 26, 1982
BC			105MG	N88020 001
				AUG 16, 1982
BC			105MG	N88028 001
				AUG 16, 1982
BC			105MG	N88062 001
				SEP 13, 1982
BC			105MG	N88063 001
				SEP 10, 1982
BC			105MG	N88111 001
				OCT 18, 1982
	@		105MG	N87214 001
				MAY 26, 1982
	@		105MG	N88020 001
				AUG 16, 1982
	@		105MG	N88028 001
				AUG 16, 1982
	@		105MG	N88062 001
				SEP 13, 1982
	@		105MG	N88063 001
				SEP 10, 1982
	@		105MG	N88111 001
				OCT 18, 1982

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

> DLT >	**AA**	INWOOD LABS	**35MG**	**N84740 001**

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE

> DLT >	**AA**	INWOOD LABS	**35MG**	**N84741 001**
> DLT >	**AA**		**35MG**	**N84742 001**
> DLT >	**AA**		**35MG**	**N84743 001**
> ADD >	@		35MG	N84740 001
> ADD >	@		35MG	N84741 001
> ADD >	@		35MG	N84742 001
> ADD >	@		35MG	N84743 001

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
PHENTERMINE HCL

AA	KING PHARMS	**30MG**	**N40083 001**
			MAR 07, 1997

TABLET; ORAL
PHENTERMINE HCL

> ADD >	**AA**	AMIDE PHARM	**37.5MG**	**N40190 001**
> ADD >				MAY 30, 1997

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL
DILANTIN

	PARKE DAVIS	30MG	N84349 001
+		30MG	N84349 001

PINDOLOL

TABLET; ORAL
PINDOLOL

AB	LEMMON	**5MG**	**N74123 001**
			APR 17, 1997
AB		**10MG**	**N74123 002**
			APR 17, 1997

PODOFILOX

GEL; TOPICAL
CONDYLOX

+	OCLASSEN	0.5%	N20529 001
			MAR 13, 1997

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS; OPHTHALMIC

		POLYTRIM					
AT	+	ALLERGAN	10,000 UNITS/ML; EQ 1MG BASE/ML	N50567 001 OCT 20, 1988			
		TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE					
AT		BAUSCH AND LOMB	10,000 UNITS/ML; EQ 1MG BASE/ML	N64120 001 FEB 14, 1997			

POTASSIUM CHLORIDE

INJECTABLE; INJECTION

			POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER					
>_DLT_>	AP	+	ABBOTT	745MG/100ML	N20161 001 NOV 30, 1992			
>_DLT_>	AP	+		14.9MG/ML	N20161 005 NOV 30, 1992			
>_ADD_>			@	745MG/100ML	N20161 001 NOV 30, 1992			
>_ADD_>			@	14.9MG/ML	N20161 005 NOV 30, 1992			
>_DLT_>	AP	+	BAXTER HLTHCARE	746MG/100ML	N19904 005 DEC 17, 1990			
>_DLT_>	AP	+		14.9MG/ML	N19904 001 DEC 26, 1989			
>_ADD_>			+	746MG/100ML	N19904 005 DEC 17, 1990			
>_ADD_>			+	14.9MG/ML	N19904 001 DEC 26, 1989			
			POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER					
>_DLT_>	AP	+	ABBOTT	1.49GM/100ML	N20161 002 NOV 30, 1992			
>_ADD_>			@	1.49GM/100ML	N20161 002 NOV 30, 1992			
>_DLT_>	AP	+	BAXTER HLTHCARE	1.49GM/100ML	N19904 006 DEC 17, 1990			
>_ADD_>			+	1.49GM/100ML	N19904 006 DEC 17, 1990			

PREDNISOLONE

TABLET; ORAL

			PREDNISOLONE					
>_DLT_>	BX		PUREPAC PHARM	5MG	N80325 001	>_ADD_>	@ PUREPAC PHARM	5MG N80325 001

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

			PREDNISOLONE ACETATE					
						>_DLT_>	STERIS	25MG/ML N83654 001
						>_ADD_>	@	25MG/ML N83654 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

			PEDIAPRED					
		+	FISONS	EQ 5MG BASE/5ML	N19157 001 MAY 28, 1986			
		+	MEDEVA	EQ 5MG BASE/5ML	N19157 001 MAY 28, 1986			

PREDNISONE

TABLET; ORAL

			PREDNISONE					
						>_DLT_>	AB HALSEY	5MG N80300 001
						>_ADD_>	@	5MG N80300 001

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

			PROCAINE HCL					
						>_DLT_>	AP STERIS	1% N83535 001
						>_DLT_>	AP	2% N83535 002
						>_ADD_>	@	1% N83535 001
						>_ADD_>	@	2% N83535 002

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION

		PROCHLORPERAZINE EDISYLATE			
AP		STERIS	EQ 5MG BASE/ML	N89605 001 JUL 08, 1987	

PROCHLORPERAZINE EDISYLATE

INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

@	STERIS	EQ 5MG BASE/ML	N89605 001	JUL 08, 1987

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCHLORPERAZINE MALEATE

> ADD >	**AB**	DURAMED	**EQ 5MG BASE**	**N40207 001**	MAY 01, 1997
> ADD >	**AB**		**EQ 10MG BASE**	**N40207 002**	MAY 01, 1997

PROGESTERONE

GEL; VAGINAL
CRINONE

+	COLUMBIA RES LABS	8%	N20756 001	MAY 13, 1997

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HCL

> DLT >	**AP**	STERIS	**25MG/ML**	**N83532 001**
> DLT >	**AP**		**50MG/ML**	**N83532 002**
> ADD >	@		25MG/ML	N83532 001
> ADD >	@		50MG/ML	N83532 002

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

BP	PAR PHARM	15MG	N88377 001	DEC 08, 1983
@		15MG	N88377 001	DEC 08, 1983

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	ROXANE	**40MG**	**N70518 001**	JUL 07, 1986
@		40MG	N70518 001	JUL 07, 1986

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION
PYRIDOXINE HCL

> DLT >	**AP**	STERIS	**100MG/ML**	**N83760 001**
> ADD >	@		100MG/ML	N83760 001

RESERPINE

TABLET; ORAL
RESERPINE

> DLT >	BP	PUREPAC PHARM	0.1MG	N80753 002
> DLT >	BP		0.25MG	N80753 001
> ADD >	@		0.1MG	N80753 002
> ADD >	@		0.25MG	N80753 001

RIFAMPIN

CAPSULE; ORAL
RIFAMPIN

AB	EON	**300MG**	**N64150 001**	MAY 28, 1997

SAMARIUM SM 153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION
QUADRAMET

CYTOGEN	50mCi/ML	N20570 001	MAR 28, 1997

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL

> DLT >	**AA**	HALSEY	**100MG**	**N84676 001**

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL
> ADD > @ HALSEY 100MG N84676 001

SELEGILINE HYDROCHLORIDE

CAPSULE; ORAL
ELDEPRYL
AB + SOMERSET **5MG** **N20647 001 MAY 15, 1996**
\+ 5MG N20647 001 MAY 15, 1996

TABLET; ORAL
SELEGILINE HCL
AB APOTHECON **5MG** **N74672 001 APR 01, 1997**
AB LEMMON **5MG** **N74744 001 JAN 27, 1997**

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION
NITROPRESS
AP ABBOTT **50MG/VIAL** **N71555 001 NOV 16, 1987**
@ 50MG/VIAL N71555 001 NOV 16, 1987

SULFAMETHOXAZOLE

SUSPENSION; ORAL
GANTANOL
\+ ROCHE 500MG/5ML N13664 002
@ 500MG/5ML N13664 002

TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL
FLOMAX
\+ BOEHRINGER INGELHEIM 0.4MG N20579 001 APR 15, 1997

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
> ADD > **MDP-BRACCO**
> ADD > **AP** BRACCO **N/A** **N18107 001**
> DLT > **MDP-SQUIBB**
> DLT > **AP** BRACCO **N/A** **N18107 001**

TERFENADINE

TABLET; ORAL
SELDANE
AB + HOECHST MARION RSSL **60MG** **N18949 001 MAY 08, 1985**
TERFENADINE
AB BAKER NORTON **60MG** **N74475 001 JAN 03, 1997**

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
> DLT > **AB** WARNER CHILCOTT **250MG** **N62300 001**
> DLT > **AB** **500MG** **N62300 002**
> ADD > @ 250MG N62300 001
> ADD > @ 500MG N62300 002

INJECTABLE; INJECTION
ACHROMYCIN
AP + LEDERLE **250MG/VIAL** **N50273 002**
AP **500MG/VIAL** **N50273 003**
\+ 250MG/VIAL N50273 002
500MG/VIAL N50273 003

TETRACYN
AP PFIZER **250MG/VIAL** **N60096 001**
AP **500MG/VIAL** **N60096 002**
@ 250MG/VIAL N60096 001
@ 500MG/VIAL N60096 002

SUSPENSION; ORAL
TETRACYCLINE HCL
AB ALPHARMA **125MG/5ML** **N60633 001**
@ 125MG/5ML N60633 001

TETRACYN
AB PFIPHARMECS **125MG/5ML** **N60095 001**
@ 125MG/5ML N60095 001

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

AP		DUPONT	1mCi/ML	N17806 001	> ADD >	
AP	+		1mCi/ML	N17806 001	> ADD >	
AP		MALLINCKRODT	1mCi/ML	N18150 001		
AP	+		1mCi/ML	N18150 001		
AP	+	MEDI PHYSICS	1mCi/ML	N18110 002		
				FEB 27, 1996		
			1mCi/ML	N18110 002		
				FEB 27, 1996		

THEOPHYLLINE

CAPSULE; ORAL
THEOPHYLLINE

BP		KV PHARM	100MG	N85263 001	
BP			200MG	N85263 002	
	@		100MG	N85263 001	> DLT >
	@		200MG	N85263 002	> DLT >

CAPSULE, EXTENDED RELEASE; ORAL
SOMOPHYLLIN-CRT

BC		GRAHAM DM	50MG	N87763 001	
				FEB 27, 1985	
BC			100MG	N87194 001	
BC			200MG	N88382 001	
				FEB 27, 1985	
BC			250MG	N87193 001	
BC			300MG	N88383 001	
				FEB 27, 1985	
	@		50MG	N87763 001	> DLT >
				FEB 27, 1985	> DLT >
	@		100MG	N87194 001	> ADD >
	@		200MG	N88382 001	> ADD >
				FEB 27, 1985	
	@		250MG	N87193 001	> ADD >
	@		300MG	N88383 001	> ADD >
				FEB 27, 1985	

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

> DLT >	AP	STERIS	100MG/ML	N83534 001	
> DLT >			200MG/ML	N83534 002	

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HCL

@	STERIS	100MG/ML	N83534 001	
@		200MG/ML	N83534 002	

TILUDRONATE DISODIUM

TABLET; ORAL
SKELID

+	SANOFI	EQ 200MG BASE	N20707 001
			MAR 07, 1997

TIMOLOL

SOLUTION/DROPS; OPHTHALMIC
BETIMOL

+	LEIRAS	EQ 0.25% BASE	N20439 001	
			MAR 31, 1995	
+		EQ 0.5% BASE	N20439 002	
			MAR 31, 1995	
+	OY STAR	EQ 0.25% BASE	N20439 001	
			MAR 31, 1995	
+		EQ 0.5% BASE	N20439 002	
			MAR 31, 1995	

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	ADV REMEDIES	EQ 0.25% BASE	N74465 001
			MAR 25, 1997
AT		EQ 0.5% BASE	N74466 001
			MAR 25, 1997
AT	AKORN	EQ 0.25% BASE	N74515 001
			MAR 25, 1997
AT		EQ 0.5% BASE	N74516 001
			MAR 25, 1997
AT	BAUSCH AND LOMB	EQ 0.25% BASE	N74778 001
			MAR 25, 1997
AT		EQ 0.5% BASE	N74776 001
			MAR 25, 1997
AT	FOUGERA	EQ 0.25% BASE	N74667 001
			MAR 25, 1997

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

AT	FOUGERA	EQ 0.5% BASE	N74668 001 MAR 25, 1997	
AT	PACIFIC PHARMA	EQ 0.25% BASE	N74746 001 MAR 25, 1997	
AT		EQ 0.5% BASE	N74747 001 MAR 25, 1997	

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

+	BRISTOL MYERS	6.5%	N19355 001 DEC 30, 1986

TOLMETIN SODIUM

TABLET; ORAL
TOLMETIN SODIUM

AB	BAKER NORTON	EQ 600MG BASE	N74399 001 MAR 28, 1996
AB	LEMMON	EQ 600MG BASE	N74729 001 FEB 27, 1997
AB	ZENITH GOLDLINE	EQ 600MG BASE	N74399 001 MAR 28, 1996

TOPIRAMATE

TABLET; ORAL
TOPAMAX

@	JOHNSON RW	400MG	N20505 006 DEC 24, 1996

> ADD > TOREMIFENE CITRATE

> ADD > TABLET; ORAL
> ADD > FARESTON

> ADD > +	ORION	EQ 60MG BASE	N20497 001 MAY 29, 1997

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL

AB	LEMMON	150MG	N74357 001 APR 30, 1997

TRETINOIN

CREAM; TOPICAL
AVITA

AB	PENEDERM	0.025%	N20404 003 JAN 14, 1997

RETIN-A

AB +	J AND J	0.025%	N19049 001 SEP 16, 1988

GEL; TOPICAL
RETIN-A MICRO

+	ADV POLYMER	0.1%	N20475 001 FEB 07, 1997

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL
TRIAMCINOLONE ACETONIDE

AT	ALPHARMA	0.1%	N87192 001 SEP 08, 1982
@		0.1%	N87192 001 SEP 08, 1982

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
TRIAMCINOLONE DIACETATE

> DLT > BP	STERIS	40MG/ML	N85529 001
> ADD > @		40MG/ML	N85529 001

TRIHEXYPHENIDYL HYDROCHLORIDE

ELIXIR; ORAL
TRIHEXYPHENIDYL HCL

AA	PHARM ASSOC	2MG/5ML	N40177 001 APR 17, 1997

TROGLITAZONE

TABLET; ORAL

	PRELAY			
AB	SANKYO	200MG	N20719 001	JAN 29, 1997
AB		400MG	N20719 002	JAN 29, 1997
	REZULIN			
AB	PARKE DAVIS	200MG	N20720 001	JAN 29, 1997
AB		400MG	N20720 002	JAN 29, 1997

> ADD > UREA C-14

> ADD > CAPSULE; ORAL

> ADD >	PYTEST			
> ADD >	+ TRI MED SPECLTS	1 uCi	N20617 001	MAY 09, 1997
> ADD >	PYTEST KIT			
> ADD >	+ TRI MED SPECLTS	1 uCi	N20617 002	MAY 09, 1997

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

	ISOPTIN SR			
> ADD > AB	+ KNOLL PHARM	120MG	N19152 003	MAR 06, 1991
	VERAPAMIL HCL			
> ADD > AB	MYLAN	120MG	N74587 002	FEB 21, 1997

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCREX			
AP	+ BRISTOL MYERS	5MG/VIAL	N70867 001	JUL 12, 1988
	@ BRISTOL MYERS SQUIBB	5MG/VIAL	N70867 001	JUL 12, 1988
	VINCRISTINE SULFATE			
AP	FAULDING	5MG/VIAL	N71561 001	APR 11, 1988

VINCRISTINE SULFATE

INJECTABLE; INJECTION

	VINCRISTINE SULFATE			
	+ FAULDING	5MG/VIAL	N71561 001	APR 11, 1988

WARFARIN SODIUM

TABLET; ORAL

	COUMADIN			
AB	DUPONT MERCK	1MG	N09218 022	MAR 01, 1990
AB	+	2MG	N09218 013	
AB		2.5MG	N09218 018	
AB		4MG	N09218 023	AUG 24, 1993
AB		5MG	N09218 007	
AB		7.5MG	N09218 016	
AB	+	10MG	N09218 005	
	WARFARIN SODIUM			
AB	BARR	1MG	N40145 001	MAR 26, 1997
AB		2MG	N40145 002	MAR 26, 1997
AB		2.5MG	N40145 003	MAR 26, 1997
AB		4MG	N40145 004	MAR 26, 1997
AB		5MG	N40145 005	MAR 26, 1997
AB		7.5MG	N40145 006	MAR 26, 1997
AB		10MG	N40145 007	MAR 26, 1997

ZINC ACETATE

CAPSULE; ORAL

	GALZIN			
	LEMMON	EQ 25MG ZINC	N20458 001	JAN 28, 1997
	+	EQ 50MG ZINC	N20458 002	JAN 28, 1997

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

COLD CAPSULE IV			
+ GRAHAM DM	12MG;75MG	N18793 001	
		APR 25, 1985	
@	12MG;75MG	N18793 001	
		APR 25, 1985	
COLD CAPSULE V			
GRAHAM DM	8MG;75MG	N18794 001	
		APR 23, 1985	
@	8MG;75MG	N18794 001	
		APR 23, 1985	

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PSEUDOEPHEDRINE HCL AND CHLORPHENIRAMINE MALEATE

> DLT > KV PHARM	12MG;120MG	N71455 001	
> DLT >		MAR 01, 1989	
> ADD > @	12MG;120MG	N71455 001	
> ADD >		MAR 01, 1989	

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

LEMMON	1.34MG	N73282 002	
		DEC 03, 1992	
TEVA	1.34MG	N73282 002	
		DEC 03, 1992	

CLOTRIMAZOLE

> DLT > CREAM, SUPPOSITORY; TOPICAL, VAGINAL			
> DLT > GYNE-LOTRIMIN 3 COMBINATION PACK			
> DLT > + SCHERING PLOUGH	1%,200MG	N20526 002	
> DLT >		JUL 29, 1996	
> DLT > GYNE-LOTRIMIN COMBINATION PACK			
> DLT > + SCHERING PLOUGH	1%,100MG	N20289 002	
> DLT >		APR 26, 1993	
> DLT > MYCELEX-7 COMBINATION PACK			
> DLT > BAYER	1%,100MG	N20389 002	
> DLT >		JUN 23, 1994	

CLOTRIMAZOLE

> ADD > CREAM, TABLET; TOPICAL, VAGINAL			
> ADD > GYNE-LOTRIMIN 3 COMBINATION PACK			
> ADD > + SCHERING PLOUGH	1%,200MG	N20526 002	
> ADD >		JUL 29, 1996	
> ADD > GYNE-LOTRIMIN COMBINATION PACK			
> ADD > + SCHERING PLOUGH	1%,100MG	N20289 002	
> ADD >		APR 26, 1993	
> ADD > MYCELEX-7 COMBINATION PACK			
> ADD > BAYER	1%,100MG	N20389 002	
> ADD >		JUN 23, 1994	
> DLT > SUPPOSITORY; VAGINAL			
> DLT > GYNE-LOTRIMIN			
> DLT > + SCHERING PLOUGH	100MG	N17717 002	
> DLT >		NOV 30, 1990	
> DLT > GYNE-LOTRIMIN 3			
> DLT > + SCHERING PLOUGH	200MG	N20525 001	
> DLT >		JUL 29, 1996	
> DLT > MYCELEX-7			
> DLT > BAYER	100MG	N18182 002	
> DLT >		DEC 26, 1991	
> ADD > TABLET; VAGINAL			
> ADD > GYNE-LOTRIMIN			
> ADD > + SCHERING PLOUGH	100MG	N17717 002	
> ADD >		NOV 30, 1990	
> ADD > GYNE-LOTRIMIN 3			
> ADD > + SCHERING PLOUGH	200MG	N20525 001	
> ADD >		JUL 29, 1996	
> ADD > MYCELEX-7			
> ADD > BAYER	100MG	N18182 002	
> ADD >		DEC 26, 1991	

CROMOLYN SODIUM

SPRAY, METERED; NASAL

NASALCROM			
+ MCNEIL	5.2MG/SPRAY	N20463 001	
		JAN 03, 1997	

IBUPROFEN

TABLET; ORAL

IBUPROFEN

> DLT > PUREPAC PHARM	200MG	N71122 001	
> DLT >		OCT 03, 1986	

IBUPROFEN

TABLET; ORAL
IBUPROFEN

> DLT >	PUREPAC PHARM	200MG	N71664 001	
> DLT >			FEB 03, 1987	
> ADD >	@	200MG	N71122 001	
> ADD >			OCT 03, 1986	
> ADD >	@	200MG	N71664 001	
> ADD >			FEB 03, 1987	

JUNIOR STRENGTH MOTRIN

MCNEIL	100MG	N20602 001	
		JUN 10, 1996	
+	100MG	N20602 001	
		JUN 10, 1996	

INSULIN SEMISYNTHETIC PURIFIED HUMAN

INJECTABLE; INJECTION
VELOSULIN BR HUMAN

+ NOVO NORDISK	100 UNITS/ML	N19450 001	
		MAY 30, 1986	

VELOSULIN HUMAN

+ NOVO NORDISK	100 UNITS/ML	N19450 001	
		MAY 30, 1986	

MICONAZOLE NITRATE

CREAM; VAGINAL
MICONAZOLE NITRATE

> ADD >	PERRIGO	2%	N74760 001
> ADD >			MAY 15, 1997
	TARO	2%	N74444 001
			JAN 13, 1997

SUPPOSITORY; VAGINAL
MICONAZOLE NITRATE

G AND W LABS	100MG	N74414 001	
		APR 30, 1997	
+ PERRIGO	100MG	N74395 001	
		MAR 20, 1997	

MINOXIDIL

SOLUTION; TOPICAL
MINOXIDIL (FOR MEN)

MORTON GROVE	2%	N74767 001
		FEB 28, 1997

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

INVAMED	EQ 200MG BASE	N74646 001
		JAN 13, 1997
NOVOPHARM	EQ 200MG BASE	N74635 001
		JAN 13, 1997
PERRIGO	EQ 200MG BASE	N74661 001
		JAN 13, 1997
PVT FORM	EQ 200MG BASE	N74789 001
		FEB 27, 1997

TIOCONAZOLE

OINTMENT; VAGINAL
VAGISTAT-1

+ BRISTOL MYERS SQUIBB	6.5%	N20676 001
		FEB 11, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 5/ MAY '97

NO MAY APPROVALS

Orphan Product Designations and Approvals List
January 1997 through May 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
8 Cyclopentyl 1,3-dipropylxanthine TN=	Treatment of cystic fibrosis.	SciClone Pharmaceuticals, Inc. 901 Mariner's Island Boulevard Suite 315 San Mateo, CA 94404 DD=03/24/1997
9-cis-retinoic acid TN=	Prevention of retinal detachment due to proliferative vitreoretinopathy.	Allergan, Inc. 2525 Dupont Drive P.O. Box 19534 Irvine, CA 92623 DD=01/02/1997
Anagrelide TN= Agrylin	Treatment of essential thrombocythemia.	Roberts Pharmaceutical Corp. Meridian Center III 6 Industrial Way West Eatontown, NJ 07724 DD=01/27/1988 MA=03/14/1997
Beta alethine TN= Betathine	Treatment of multiple myeloma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Beta alethine TN= Betathine	Treatment of metastatic melanoma.	Dovetail Technologies, Inc. 10615 Mantz Road Silver Spring, MD 20903 DD=03/24/1997
Coagulation Factor IX (recombinant) TN= BeneFix	Treatment of hemophilia B.	Genetics Institute, Inc. 87 Cambridge Park Drive Cambridge, MA 02140 DD=10/03/1994 MA=02/11/1997

Orphan Product Designations and Approvals List
January 1997 through May 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Dehydroepiandrosterone sulfate sodium TN=	To accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/28/1997
Dehydroepiandrosterone sulfate sodium TN=	Treatment of serious burns requiring hospitalization.	Pharmadigm, Inc. 2401 Foothill Drive Salt Lake City, UT 84109 DD=01/29/1997
Dimethylsulfoxide TN=	Topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.	Cancer Technologies, Inc. 7301 East 22nd Street Suite 10E Tucson, AZ 85710 DD=04/15/1997
Enadoline hydrochloride TN=	Treatment of severe head injury.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=01/28/1997
Gp100 adenoviral gene therapy TN=	Treatment of metastatic melanoma.	Genzyme Corporation P.O. Box 9322 One Mountain Road Framingham, MA 01701 DD=03/25/1997
Lepirudin TN= Refludan	Treatment of heparin-associated thrombocytopenia Type II.	Behringwerke AG P.O. Box 1140 D-35001 Marburg Germany, DD=02/13/1997

Orphan Product Designations and Approvals List
January 1997 through May 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Levocarnitine TN= Carnitor	Treatment of zidovudine-induced mitochondrial myopathy.	Sigma-Tau Pharmaceuticals, Inc. 800 S. Frederick Avenue, Suite 300 Gaithersburg, MD 20877 DD=04/07/1997
MART-1 adenoviral gene therapy for malignant melanoma TN=	Treatment of metastatic melanoma.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=03/28/1997
Oxandrolone TN= Oxandrin	Treatment of patients with Duchenne's muscular dystrophy and Becker's muscular dystrophy.	Bio-Technology General Corporation 70 Wood Avenue South Iselin, NJ 08830 DD=04/22/1997
Paclitaxel TN= Taxol	Treatment of AIDS-related Kaposi's sarcoma.	Bristol-Myers Squibb Pharmaceutical Research Institute 5 Research Parkway P.O. Box 5100 Wallingford, CT 06492 DD=03/25/1997
Paclitaxel TN= Paxene	Treatment of AIDS-related Kaposi's sarcoma.	Baker Norton Pharmaceuticals, Inc. 4400 Biscayne Boulevard Miami, FL 33137 DD=04/15/1997
Patul-end TN=	Treatment of patulous eustachian tube.	Ear Foundation 24209 Castillo Street, Suite 100 Santa Barbara, CA 93105 DD=02/18/1997

Orphan Product Designations and Approvals List
January 1997 through May 1997

Name Generic Name TN=Trade Name	Indication Designated	Sponsor & Address DD= Date Designated MA=Marketing Approval
Poly-ICLC TN=	Treatment of primary brain tumors.	Salazar, Andres M. M.D. and Levy, Hilton B. Ph.D. 3202 Cleveland Avenue N.W. Washington, DC 20008 DD=03/17/1997
Porfiromycin TN= Promycin	Treatment of cervical cancer.	Vion Pharmaceuticals, Inc. Four Science Park New Haven, CT 06511 DD=03/13/1997
Retroviral vector, R-GC and GC gene 1750 TN=	Treatment of Gaucher disease.	Genzyme Corporation One Kendall Square Cambridge, MA 02139 DD=05/06/1997
Suramin TN=	Treatment of metastatic hormone-refractory prostate cancer.	Warner-Lambert Company Parke-Davis Pharmaceutical Research Division 2800 Plymouth Road Ann Arbor, MI 48105 DD=05/06/1997
Zinc acetate TN= Galzin	Treatment of Wilson's disease.	Lemmon Company 1510 Delp Drive Kulpsville, PA 19443 DD=11/06/1985 MA=01/28/1997

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO MAY 1997 ADDITIONS

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 17TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-33	ONCE DAILY DOSING FOR PLAQUE PSORIASIS

NEW INDICATION

I-177	TREATMENT OF MODERATE ACNE VULGARIS IN FEMALES, GREATER OR EQUAL TO 15 YEARS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, DESIRE CONTRACEPTION, HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS
I-178	TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN
I-179	NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE
I-180	TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE)
I-181	TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION
I-182	TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME
I-183	MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11
I-184	TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2 MG/DAY (MAXIMUM OF 4MG)
I-185	PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
I-186	TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE)
I-187	PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS

PATENT USE CODE

U-161	METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT
U-162	METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA
U-163	METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS
U-164	METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS
U-165	TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA
U-166	TREATMENT OF H. PYLORI ASSOCIATED DUODENAL ULCER
U-167	METHOD FOR TREATING HIV-1 INFECTION
U-168	METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA
U-169	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING
U-170	METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT

EXCLUSIVITY TERMS

PATENT USE CODE

U-171	METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRAC
U-172	TREATMENT OF GENITAL WARTS
U-173	ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES
U-174	USE AS AN ANTIHISTAMINE AGENT
U-175	METHOD OF TREATING MALIGNANT TUMORS
U-176	METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSIS
U-177	FUNGICIDE
U-178	FACILITATED ADHERENCE OF AGENTS TO SKIN
U-179	ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT
U-180	TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION
U-181	PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST
U-182	USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION
U-183	TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020059	001	ADENOSINE;ADENOSCAN	5070877	MAY 18, 2009	U-116		
	020291	001	ALBUTEROL SULFATE;COMBIVENT	5603918	JUN 09, 2015		NC	OCT 24, 1999
	020503	001	ALBUTEROL SULFATE;PROVENTIL-HFA	5225183	JUL 06, 2010		NP	AUG 15, 1999
				5439670	JUL 06, 2010			
				5605674	FEB 25, 2014			
	020560	001	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
>ADD>							I-187	APR 25, 2000
	020560	002	ALENDRONATE SODIUM;FOSAMAX				I-185	APR 25, 2000
>ADD>							I-187	APR 25, 2000
	020560	003	ALENDRONATE SODIUM;FOSAMAX	5358941	DEC 02, 2012		NS	APR 25, 2000
				4621077	NOV 04, 2003	U-114	I-185	APR 25, 2000
>ADD>							I-187	APR 25, 2000
	020333	001	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
	020333	002	ANAGRELIDE HYDROCHLORIDE;AGRYLIN				ODE	MAR 14, 2004
							NCE	MAR 14, 2002
>ADD>	020227	002	ARDEPARIN SODIUM;NORMIFLO				NCE	MAY 23, 2002
	020702	001	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020702	002	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020702	003	ATORVASTATIN CALCIUM;LIPITOR	4681893	MAY 30, 2006	U-161	NCE	DEC 17, 2001
				5273995	DEC 28, 2010	U-162		
				5385929	MAY 04, 2014	U-59		
	020486	001	BECLOMETHASONE DIPROPIONATE;VANCERIL DOUBLE STRENGTH				NP	DEC 24, 1999
	020032	001	BERACTANT;SURVANTA	4397839	JUL 01, 2005			
	020619	001	BETAXOLOL HYDROCHLORIDE;BETOPTIC PILO				NC	APR 17, 2000
	020490	001	BRIMONIDINE TARTRATE;ALPHAGAN				NP	MAR 13, 2000
							NCE	SEP 06, 2001
	018644	002	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
	018644	003	BUPROPION HYDROCHLORIDE;WELLBUTRIN	5358970	AUG 12, 2013			
>ADD>	020711	002	BUPROPION HYDROCHLORIDE;ZYBAN				NP	MAY 14, 2000
>ADD>	020711	003	BUPROPION HYDROCHLORIDE;ZYBAN				NP	MAY 14, 2000
	020524	001	BUTENAFINE HYDROCHLORIDE;MENTAX	5021458	JUN 04, 2008	U-177		
	019881	001	BUTOCONAZOLE NITRATE;FEMSTAT ONE	4078071	MAR 07, 1997		NP	FEB 07, 2000
	020664	001	CABERGOLINE;DOSTINEX	4526892	JUL 02, 2002		NCE	DEC 23, 2001
	020273	001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		D-33	MAR 20, 2000
	020554	001	CALCIPOTRIENE;DOVONEX				NCE	DEC 29, 1998
	020611	001	CALCIPOTRIENE;DOVONEX	4866048	SEP 12, 2006		NDF	MAR 03, 2000
							NCE	DEC 29, 1998
	019880	001	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	002	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019880	003	CARBOPLATIN;PARAPLATIN	4657927	APR 14, 2004	U-175		
	019835	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
	019835	002	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020346	001	CETIRIZINE HYDROCHLORIDE;ZYRTEC	4525358	JUN 25, 2007			
>ADD>	019537	001	CIPROFLOXACIN HYDROCHLORIDE;CIPRO	5286754	FEB 15, 2011			
>ADD>				4670444	DEC 09, 2003	U-36		
	019847	001	CIPROFLOXACIN;CIPRO	4705789	NOV 10, 2004		I-179	OCT 21, 1999
	019857	001	CIPROFLOXACIN;CIPRO IN DEXTROSE 5%	4808583	FEB 28, 2006		I-179	OCT 21, 1999
	019858	001	CIPROFLOXACIN;CIPRO IN SODIUM CHLORIDE 0.9%	4705789	NOV 10, 2004		I-179	OCT 21, 1999
	017533	001	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	002	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	003	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	005	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	017533	006	CLONAZEPAM;KLONOPIN				I-184	APR 09, 2000
	020463	001	CROMOLYN SODIUM;NASALCROM				NP	JAN 03, 2000
	020430	001	DANAPAROID SODIUM;ORGARAN	5164377	OCT 03, 2010			
	020705	001	DELAVIRDINE MESYLATE;RESCRIPTOR	5563142	OCT 08, 2013		NCE	APR 04, 2002
	020037	001	DICLOFENAC SODIUM;VOLTAREN	4960799	OCT 03, 2007			
				4829088	APR 14, 2007			
	020154	002	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020154	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020154	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
	020154	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	004	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	020155	005	DIDANOSINE;VIDEX	5616566	AUG 29, 2000	U-180		
	020156	001	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
	018723	001	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	002	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	018723	003	DIVALPROEX SODIUM;DEPAKOTE				I-181	JUN 20, 1999
	019680	001	DIVALPROEX SODIUM;DEPAKOTE	4988731	JAN 29, 2008		I-181	JUN 20, 1999
	020668	001	ENALAPRIL MALEATE;LEXXEL	4472380	SEP 18, 2001			
				4374829	DEC 30, 2001	U-3		
				4703038	OCT 07, 2005	U-3		
	020417	001	ESTRADIOL;FEMPATCH	4906463	MAR 06, 2007		NP	DEC 03, 1999
				5006342	APR 09, 2008			
	019697	001	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	019697	002	ETHINYL ESTRADIOL;ORTHO TRI-CYCLEN	4544554	SEP 26, 2003	U-66	I-177	DEC 31, 1999
	018922	005	ETODOLAC;LODINE				I-24	JUN 28, 1999
	020410	001	FERUMOXSIL;GASTROMARK	5219554	JUN 15, 2010		NCE	DEC 06, 2001
				5069216	MAY 09, 2006	U-171		
				5055288	OCT 08, 2008			
				4951675	SEP 13, 2005	U-169		
				4827945	MAY 09, 2006	U-170		
				4770183	SEP 13, 2005	U-169		
				4695393	SEP 22, 2004			
				4695392	SEP 22, 2004			
>ADD>	020038	001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	FEB 24, 2003			
>DLT>	020038	001	FLUDARABINE PHOSPHATE;FLUDARA	4357324	NOV 02, 2001			
	020235	001	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020235	002	GABAPENTIN;NEURONTIN	4087544	JAN 16, 2000			
>ADD>	020235	003	GABAPENTIN;NEURONTIN	4894476	MAY 02, 2008			
>DLT>	020235	003	GABAPENTIN;NEURONTIN	4894476	JAN 16, 2007			
				4087544	JAN 16, 2000			
	020622	001	GLATIRAMER ACETATE;COPAXONE				ODE	DEC 20, 2003
	020329	001	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
	020329	002	GLIPIZIDE;GLUCOTROL XL	5591454	JAN 07, 2014	U-150		
	020267	002	IBUPROFEN;JUNIOR STRENGTH ADVIL				NP	JUN 16, 1998
	020723	001	IMIQUIMOD;ALDARA	4689338	AUG 25, 2004	U-172	NCE	FEB 27, 2002
				5238944	AUG 24, 2010			
	040024	001	IRON DEXTRAN;DEXFERRUM	5624668	SEP 29, 2015			
	020083	001	ITRACONAZOLE;SPORANOX				I-178	DEC 06, 1999
	020657	001	ITRACONAZOLE;SPORANOX				NDF	FEB 21, 2000
>ADD>	019927	001	KETOCONAZOLE;NIZORAL				I-186	MAY 30, 2000
>ADD>	020708	001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631020	MAY 20, 2014		NP	MAR 07, 2000
>ADD>				5631021	MAY 20, 2014			
>ADD>				4652441	NOV 01, 2004			
				4652411	NOV 01, 2004			
				4677191	JUL 03, 2005			
				4728721	MAY 01, 2006			
				4849228	JUL 18, 2006			
				4917893	NOV 01, 2004			
				4954298	NOV 01, 2004			
				5330767	NOV 01, 2004			
				5476663	APR 17, 2007			
				5480656	JAN 02, 2013			
				5575987	NOV 19, 2013			
	020641	001	LORATADINE;CLARITIN	4659716	APR 21, 2004	U-142		
	020704	001	LORATADINE;CLARITIN REDITABS	4282233	JUN 19, 2002	U-77	NCE	APR 12, 1998
				4659716	APR 21, 2004	U-142		
	020357	001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	020357	002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				NCE	MAR 03, 2000
	019660	001	NEDOCROMIL SODIUM;TILADE				I-183	MAR 06, 2000
	020778	001	NELFINAVIR MESYLATE;VIRACEPT				NCE	MAR 14, 2002
	020779	001	NELFINAVIR MESYLATE;VIRACEPT				NCE	MAR 14, 2002
	020636	001	NEVIRAPINE;VIRAMUNE	5366972	NOV 22, 2011	U-167	NCE	JUN 21, 2001
>ADD>	020714	001	NICOTINE;NICOTROL				NP	MAY 02, 2000
	020592	001	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	002	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	003	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020592	004	OLANZAPINE;ZYPREXA	5605897	FEB 25, 2014	U-176		
	020688	001	OLOPATADINE HYDROCHLORIDE;PATANOL	4871865	OCT 03, 2006			
				4923892	MAY 08, 2007	U-174		
				5116863	MAY 26, 2009			
	019810	001	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019810	003	OMEPRAZOLE;PRILOSEC	4636499	MAY 30, 2005			
				5093342	FEB 02, 2010	U-166		
				5599794	FEB 04, 2014	U-166		
>ADD>	020605	001	ONDANSETRON HYDROCHLORIDE;ZOFRAN	4753789	JUN 24, 2006	U-44		
>ADD>				4695578	JUN 25, 2005	U-183		
				5578628	JUN 24, 2006	U-44		
	020031	001	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
	020031	002	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
	020031	003	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
	020031	004	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
	020031	005	PAROXETINE HYDROCHLORIDE;PAXIL	4721723	DEC 29, 2006		I-150	MAY 07, 1999
>ADD>	019385	001	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
>ADD>	019385	002	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
>ADD>	019385	003	PERGOLIDE MESYLATE;PERMAX	5114948	OCT 19, 2009			
	018796	001	PILOCARPINE HYDROCHLORIDE;PILOPINE HS	4271143	MAY 09, 1999			
	020529	001	PODOFILOX;CONDYLOX	4680399	JUL 14, 2004		NDF	MAR 13, 2000
				5057616	OCT 15, 2008			
>ADD>	020756	001	PROGESTERONE;CRINONE				NP	MAY 13, 2000
	019627	002	PROPOFOL;DIPRIVAN				NP	JUN 11, 1999
	020272	001	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	002	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	003	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020272	004	RISPERIDONE;RISPERDAL	5158952	OCT 27, 2009	U-90		
	020588	001	RISPERIDONE;RISPERDAL	5453425	JUN 11, 2014			
				5616587	JUN 11, 2014			
	020236	001	SALMETEROL XINAFOATE;SEREVENT	5380922	JAN 10, 2012			
				5225445	FEB 12, 2008	U-182		
	020570	001	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET				NCE	MAR 28, 2002
	020570	002	SAMARIUM SM 153 LEXIDRONAM PENTASODIUM;QUADRAMET				NCE	MAR 28, 2002
	019640	001	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
>ADD>							I-182	DEC 30, 1999
	019640	004	SOMATROPIN, BIOSYNTHETIC;HUMATROPE				ODE	DEC 30, 2003
>ADD>							I-182	DEC 30, 1999
	020168	001	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	020168	002	SOMATROPIN, BIOSYNTHETIC;NUTROPIN				ODE	DEC 30, 2003
							I-182	DEC 30, 1999
	020579	001	TAMSULOSIN HYDROCHLORIDE;FLOMAX	4868216	SEP 19, 2006	U-181	NCE	APR 15, 2002
				4731478	OCT 27, 2004			
				4703063	OCT 27, 2004			
				4772475	FEB 27, 2006			
	019057	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019057	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	019057	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5504207	APR 29, 2013			
				5294615	APR 29, 2013	U-165		
						U-3		
	020347	001	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-3		
						U-165		
	020347	002	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	003	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020347	004	TERAZOSIN HYDROCHLORIDE;HYTRIN	5294615	APR 29, 2013	U-165		
						U-3		
	020192	001	TERBINAFINE HYDROCHLORIDE;LAMISIL				I-180	JAN 21, 2000
	020707	001	TILUDRONATE DISODIUM;SKELID	4876248	OCT 24, 2006		NCE	MAR 07, 2002
				4980171	APR 06, 2009			
	020676	001	TIOCONAZOLE;VAGISTAT-1				NP	FEB 11, 2000
>ADD>	020497	001	TOREMIFENE CITRATE;FARESTON				NCE	MAY 29, 2002
	020404	003	TRETINOIN;AVITA	4971800	NOV 20, 2007	U-178		
				5045317	SEP 03, 2008	U-179		
	020475	001	TRETINOIN;RETIN-A MICRO	4690825	OCT 04, 2005	U-134	NP	FEB 07, 2000
	020326	001	TRIMETREXATE GLUCURONATE;NEUTREXIN	4376858	MAY 09, 2004			
	020719	001	TROGLITAZONE;PRELAY	5478852	SEP 15, 2013	U-163	NCE	JAN 29, 2002
				5457109	SEP 15, 2013	U-164		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5602133	SEP 15, 2013	U-173		
	020719	002	TROGLITAZONE;PRELAY	5478852	SEP 15, 2013	U-163	NCE	JAN 29, 2002
				5457109	SEP 15, 2013	U-164		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5602133	SEP 15, 2013	U-173		
	020720	001	TROGLITAZONE;REZULIN	5478852	SEP 15, 2013	U-163	NCE	JAN 29, 2002
				5457109	SEP 15, 2013	U-164		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5602133	SEP 15, 2013	U-173		
	020720	002	TROGLITAZONE;REZULIN	5478852	SEP 15, 2013	U-163	NCE	JAN 29, 2002
				5457109	SEP 15, 2013	U-164		
				4572912	AUG 28, 2004			
				5104888	AUG 28, 2004			
				5602133	SEP 15, 2013	U-173		
>ADD>	020617	001	UREA C-14;PYTEST				NCE	MAY 09, 2002
>ADD>	020617	002	UREA C-14;PYTEST KIT				NCE	MAY 09, 2002
	020665	001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		
	020665	002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012	U-3		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER		INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020471	001	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
020471	003	ZILEUTON;ZYFLO	4873259	FEB 10, 2007	U-168		
020458	001	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
						ODE	JAN 28, 2004
020458	002	ZINC ACETATE;GALZIN				NP	JAN 28, 2000
						ODE	JAN 28, 2004

*U.S. Government Printing Office: 1997 - 417-599/40012

New 17th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

17TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7971

Charge your order. It's easy!

MasterCard VISA

☐ **Yes,** enter my subscription as follows:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $77.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(_____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature) (10/96)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.